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ABSTRACT 
 
Alzheimer’s disease (AD) is associated with progressive cognitive declines that 
classically affect memory in the mild stages of the disease and gradually impair all other 
cognitive functions. Although certain changes in cognitive abilities are known to be 
associated with AD, better characterization of how cognitive functions become impaired 
relative to each other is needed to improve our understanding of AD. 
It is also vital to better understand how and why AD affects women differently 
than men. Almost two-thirds of individuals with AD in the United States are women, 
and several studies have shown that women are at higher risk of developing AD. Among 
those with AD, women seem to have worse cognitive deficits than men. It is unclear why 
women may be more vulnerable to AD than men. 
The potential contribution of neuropsychiatric symptoms to the gender gap in AD 
has not been considered carefully. Neuropsychiatric symptoms (e.g., depression, 
anxiety) are commonly experienced by individuals with AD, but these emotional 
symptoms often differ between men and women. Furthermore, neuropsychiatric 
symptoms are associated with risk for AD and accelerated cognitive deterioration. 
Neuropsychiatric symptoms may mediate the gender gap in AD, but this hypothesis has 
not been analyzed. 
Given these important, unanswered questions about the relationships among 
cognitive dysfunction, gender, and neuropsychiatric symptoms in AD, the current 
research (1) developed cross-sectional and longitudinal models of AD-associated 
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cognitive dysfunction, (2) analyzed gender differences in these models, (3) examined 
whether neuropsychiatric symptoms mediated any gender differences in AD-associated 
cognitive dysfunction, and (4) analyzed whether gender or neuropsychiatric symptoms 
predicted conversion from non-demented aging to AD. 
Results indicated that individuals with AD experienced linear cognitive decline 
over a two-year period. Among individuals with AD, women had worse memory 
performance and exhibited faster rates of memory decline than men. Neuropsychiatric 
symptoms did not mediate these gender effects on AD-associated cognitive dysfunction, 
but they did increase odds of conversion from non-demented aging to AD. However, 
gender did not predict likelihood of converting to AD. Overall, this study suggested that 
AD-afflicted women may suffer from worse memory dysfunction than their male 
counterparts, even when controlling for dementia severity.  
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INTRODUCTION AND LITERATURE REVIEW 
Alzheimer’s disease (AD) is a major health and societal concern that currently 
affects an estimated 5.3 million Americans (Alzheimer’s Association, 2015). AD is the 
sixth leading cause of death in the United States and is projected to affect 13.8 million 
Americans over the age of 65 years by 2050 (Alzheimer’s Association, 2015). 
Worldwide, AD is projected to affect 106.2 million older adults by 2050 (Brookmeyer, 
Johnson, Ziegler-Graham, & Arrighi, 2007). Considering these staggering estimates and 
current lack of disease-modifying or preventative treatments, effective interventions and 
prevention are needed more than ever. Toward this end, research has been aimed at 
better understanding the disease as a whole, with a particular focus on characterizing 
early symptoms and predictors of future decline. 
AD is conceptualized as a disease spectrum or continuum (Carrillo et al., 2012), 
rather than a static disease state. AD is not a consequence of normal or accelerated aging 
(Fjell et al., 2014; Nelson et al., 2011, 2012), but rather a distinct disease with insidious 
onset. AD advances progressively and spans a continuum across preclinical AD 
(Sperling et al., 2011), mild cognitive impairment (MCI; Albert et al., 2011; Petersen et 
al., 2001; Petersen, 2004), and dementia due to AD (McKhann et al., 2011). The 
preclinical stage is characterized by the development of disease pathology in the brain. 
Subjective memory concerns can also develop in this early stage, but objective cognitive 
performance is predominantly preserved. As the disease progresses, cognitive 
impairment becomes overt and measurable on neuropsychological assessment, such that 
individuals meet criteria for MCI. Cognitive declines gradually become more prominent 
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and affect one’s capacity to care for oneself and complete important daily activities, at 
which point the person meets criteria for dementia due to AD.  
It can be useful to consider these important clinical diagnostic stages along the 
AD continuum, but it is also essential to remember that the disease itself is progressive 
and so each of these stages represent a range of severity along a dimension (Backman, 
Jones, Berger, Laukka, & Small, 2005; Balsis, Miller, Benge, & Doody, 2011; Miller, 
Balsis, Lowe, Benge, & Doody, 2011). Although the emergence or increased severity of 
certain clinical symptoms, such as deterioration of cognition and ability to complete 
daily activities, is linked to conversion between diagnostic stages (e.g., conversion from 
MCI to dementia), the disease itself advances in a progressive manner rather than a 
stepwise, categorical manner. 
As a neurodegenerative condition, AD is marked by a pattern of abnormalities 
within the brain that disrupt neurochemical and neuroanatomical integrity. Two of the 
earliest markers of AD are abnormal accumulation of amyloid-beta (Hardy & Higgins, 
1992; Hardy & Selkoe, 2002) and pathological tau formation (Ballatore, Lee, & 
Trojanowski, 2007; Braak & Braak, 1995; Braak, Thal, Ghebremedhin, & Del Tredici, 
2011), causing the development of amyloid plaques and neurofibrillary tangles, hallmark 
signs of AD (Ittner & Gotz, 2011; Risacher & Saykin, 2013). The plaques and tangles 
cause synaptic dysfunction and reduced regionalized cerebral activity, which can be 
measured by reduced glucose metabolism on functional neuroimaging (e.g., FDG-PET 
scans). Changes in neural activity parallel the pattern of neuroanatomical volumetric 
losses (Chen et al., 2010; Mosconi et al., 2008). Structural brain changes initially affect 
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the medial temporal lobe, specifically first in the entorhinal cortex, followed by thinning 
of the hippocampus and associated regions (Desikan et al., 2010; Devanand et al., 2012; 
Jiji, Smitha, Gupta, Pillai, & Jayasree, 2013; Johnson, Fox, Sperling, & Klunk, 2012; 
Schuff et al., 2009). As the disease progresses, ventricles expand and brain atrophy 
becomes globalized and severe (Scahill, Schott, Stevens, Rossor, & Fox, 2002; Whitwell 
et al., 2007).  
Recent theoretical models have proposed a sequence of how key disease markers 
may change along the course of AD (Jack et al., 2010, 2013; Sperling et al., 2011). 
These models propose that markers of synaptic dysfunction emerge early in the disease, 
followed by indicators of cortical atrophy and later by cognitive decline. However, there 
is also evidence that suggests that hippocampal volume, synaptic dysfunction (measured 
by FDG-PET imaging), and global cognition may actually decline simultaneously 
(Bertens, Knol, Scheltens, Visser, & Alzheimer’s Disease Neuroimaging Initiative, 
2015). These models represent cognition as a single entity when there are numerous 
cognitive functions that have distinct trajectories in AD (e.g., Carter, Caine, Burns, 
Herholz, & Lambon Ralph, 2012). So while these theoretical models are useful for 
guiding future research efforts and promoting a broad, unified approach to analyzing 
AD, these disease models need to be validated and specific cognitive processes need to 
be integrated into the models. 
Cognitive Declines in Alzheimer’s Disease 
As AD impairs neuronal function and brain structure, cognitive dysfunction 
develops beyond what is consistent with normal aging-related cognitive declines. Within 
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a healthy older adult population without cognitive impairment, normal cognitive aging 
patterns show steady declines in certain cognitive abilities, but improvements in other 
skills. Older adults show improvements in cognitive abilities, such as vocabulary and 
general knowledge, as they age (Park et al., 2002; Salthouse, 2004; Salthouse, Atkinson, 
& Berish, 2003). However, beginning in early adulthood (Salthouse, 2009b), there are 
nearly linear declines in processing speed, visuospatial abilities, executive functions, 
language skills, and verbal and visuospatial memory (Bopp & Verhaeghen, 2005; Caselli 
et al., 2014; Jacobs et al., 1995; Nyberg, Lovden, Riklund, Lindenberger, & Backman, 
2012; Park et al., 2002; Salthouse, 2004, 2009a; Salthouse, Atkinson, & Berish, 2003; 
Salthouse & Meinz, 1995; Wilson et al., 2002).  
While there are these steady cognitive declines in non-diseased aging, the 
declines are much more dramatic in AD. On cognitive assessment, individuals who 
develop AD can be differentiated from older adults who perform within expected limits 
for their age (and therefore are considered cognitively healthy or “normal”). Individuals 
with MCI and AD dementia perform significantly below their same-age peers on 
neuropsychological measures (e.g., Backman et al., 2005; Salthouse & Becker, 1998). 
There are also significant differences in baseline cognitive performance between older 
adults who remain cognitively healthy over time and those who were cognitively intact 
at baseline but eventually develop AD (Rubin et al., 1998; Tierney, Yao, Kiss, & 
McDowell, 2005). 
Progressive declines in cognitive performance become increasingly evident with 
worsening AD severity, but subtle cognitive changes may develop earlier in the disease 
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process than previously thought (Schmid, Taylor, Foldi, Berres, & Monsch, 2013; 
Sperling et al., 2011). In fact, there is a large body of evidence that cognitive functions 
begin to change several years before clinical diagnosis (Backman et al., 2005; Elias et 
al., 2000; Linn et al., 1995; Salmon & Bondi, 2009; Saxton et al., 2004; Wilson et al., 
2012).  
One longitudinal study (Wilson et al., 2012) found that global cognitive function 
changed at a nonlinear rate and began to decline about 7.5 years prior to a diagnosis of 
dementia. Cognitive decline rapidly accelerated about 5.5 years later, approximately 2 
years prior to dementia diagnosis, and continued to decline at this quick rate even 
beyond diagnosis of dementia. This is consistent with other longitudinal studies that 
showed a steady decline in global cognition (assessed by the Mini-Mental Status 
Examination; MMSE) for several years prior to dementia diagnosis (Small, Fratiglioni, 
Viitanen, Winblad, & Backman, 2000), with accelerated decline in the three years prior 
to diagnosis (Amieva et al., 2008; Small & Backman, 2007). Other global measures of 
cognition, such as the Clinical Dementia Rating scale (CDR), MMSE, and Alzheimer’s 
Disease Assessment Scale-Cognitive (ADAS-Cog), have been shown to decline more 
quickly in individuals with MCI than in individuals with preclinical AD (Bertens et al., 
2015). Even individuals with subjective memory concerns but no overt cognitive 
impairment at initial testing show disproportionate declines over time on measures of 
global cognition compared to healthy controls (Chamberlain et al., 2011). These early 
deficits in global cognition are supported by meta-analytic findings that individuals who 
were later diagnosed with AD had significantly lower baseline scores on tests of global 
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cognition (e.g., MMSE) than individuals who did not develop AD (Backman et al., 
2005; Tierney et al., 2005).  
Patterns of cognitive deterioration parallel the spread of AD throughout the brain. 
Just as AD initially affects the medial temporal lobe and then spreads throughout the 
brain, AD causes disproportionate declines in specific cognitive functions and is 
associated with a classic neuropsychological profile. Early cognitive declines reflect the 
impact of the disease on the medial temporal lobe, so early deficits develop in episodic 
memory (Buckner, 2004; Caselli et al., 2014; Linn et al., 1995; Mickes et al., 2007; 
Saxton et al., 2004), followed by difficulty in other areas of learning and memory. AD 
can also be marked by early declines in nonamnestic cognitive domains, such as 
complex executive or language functions (Albert et al., 2011; Sacuiu, Sjogren, 
Johansson, Gustafson, & Skoog, 2005; Salmon & Bondi, 2009). Declines in semantic 
memory, verbal fluency, and verbal concept formation have been shown as early as 10 to 
12 years prior to diagnosis with dementia (Amieva et al., 2008). Individuals with MCI 
show faster rates of decline in executive and memory measures compared to individuals 
with preclinical AD who do not yet meet criteria for MCI or dementia due to AD 
(Bertens et al., 2015). 
A recent study (Mura et al., 2014) examined how well various 
neuropsychological measures could detect cognitive change in individuals with MCI 
who either converted to AD within a three-year period or remained stable. The authors 
found that individuals with MCI who later converted to AD showed significant declines 
over time on tests of language, verbal episodic memory, and working memory compared 
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to individuals with MCI who did not convert to AD. Differences in annual change 
between the two groups were largest on tests of language and verbal episodic memory. 
There were smaller but still significantly different rates of annual change between the 
two groups on select measures of processing speed, visual memory, and working 
memory (measured by Trail Making Test Part A, Benton Visual Retention Test, and 
Serial Digit Ordering Test, respectively). Surprisingly, there were no significant group 
differences in terms of mean annual change for a classic executive measure of visual set 
shifting (i.e., Trail Making Test Part B), nor two measures of verbal abstraction and 
psychomotor speed (i.e., WAIS Similarities and WAIS Digit Symbol Test).  
Furthermore, Mura and colleagues (2014) demonstrated that each of these 
neuropsychological tests had a different psychometric ability to measure cognitive 
ability. Since each of these neuropsychological tests had a different relationship to latent 
cognition, this finding also indicates that each test has differential sensitivity to 
measuring cognitive change. Based on these results, the researchers concluded that tests 
measuring verbal episodic memory and language were more sensitive to detecting 
cognitive change in MCI than tests of immediate visual memory, verbal concept 
abstraction, and executive function.  
Backman and colleagues (2005) conducted an important meta-analysis to 
examine baseline differences in a wide range of cognitive functions between individuals 
who were later diagnosed with AD and individuals who did not later develop AD. The 
investigators found that at baseline, subjects with preclinical AD (i.e., those who were 
later diagnosed with AD) had significantly lower performance at baseline on numerous 
  8 
cognitive tasks compared to control subjects (i.e., those who did not later develop AD). 
Specifically, the preclinical AD group showed significant deficits in episodic memory, 
verbal ability, visuospatial skill, attention, perceptual speed, and executive functioning at 
baseline. The effect sizes were large for perceptual speed (d = 1.11), executive 
functioning (d = 1.07), and episodic memory (d = 1.03). There were moderate but still 
noteworthy effect sizes for verbal ability (d = 0.79), visuospatial skill (d = 0.64), and 
attention (d = 0.62). The only cognitive domain that did not show significant differences 
between those who later developed AD versus those who did not was primary memory, 
consisting of tasks involving basic attention and sensory memory (e.g., WAIS Digit 
Span-Forward). As the authors note, these findings support the emergence of early 
declines in episodic memory, but they also indicate that numerous other cognitive 
functions are affected in preclinical AD. Effect sizes for episodic memory, executive 
functioning, and perceptual speed were virtually indistinguishable and had overlapping 
confidence intervals, suggesting that executive dysfunction and perceptual slowing may 
represent prominent cognitive declines on par with episodic memory difficulties in 
preclinical AD.  
As AD severity intensifies, cognitive performance continues to decline in 
memory and across all other cognitive functions, including attention, executive, 
language, processing speed, and visuospatial abilities (Salmon & Bondi, 2009). As noted 
previously, in addition to memory dysfunction, early deficits may influence executive 
abilities (including mental manipulation of information, problem solving, and set 
shifting) and language (including deficits in verbal fluency and confrontation naming). 
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As the disease progresses, deficits in attention and visuospatial abilities become more 
evident (Saxton et al., 2004). Although impairment on complex attentional tasks may 
develop in early AD, basic attentional processes involved in focusing and sustaining 
attention do not decline until later in the disease (Weintraub, Wicklund, & Salmon, 
2012). Cognitive functions continue to decline and may even deteriorate at an 
accelerated rate in the last few years prior to death (Wilson, Leurgans, Boyle, Schneider, 
& Bennett, 2010). 
Although certain changes in cognitive abilities are known to be associated with 
AD, research continues to refine our understanding of how cognitive difficulties emerge 
consequent to the disease. We need more longitudinal studies that examine trajectories 
of change across a wide range of cognitive functions in AD. Better characterization of 
how cognitive functions are impaired and change across the course of the disease is 
needed to improve our understanding of AD.  
Neuropsychiatric Symptoms in Alzheimer’s Disease 
In addition to cognitive dysfunction, individuals with AD frequently experience 
emotional and behavioral symptoms, often referred to as neuropsychiatric symptoms. 
Neuropsychiatric symptoms increase with dementia severity (Canevelli et al., 2013), so 
they are more common among individuals with MCI and AD relative to those with 
healthy cognitive functioning. In a population-based study, 27% of cognitively healthy 
older adults reported at least one neuropsychiatric symptom, whereas 51% of adults with 
MCI reported at least one neuropsychiatric symptom (Geda et al., 2008). Similarly, other 
studies report that between 35-85% of individuals with MCI experience at least one 
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neuropsychiatric symptom (Apostolova & Cummings, 2008; Gallagher et al., 2010; Van 
der Mussele et al., 2014). Individuals with AD dementia also commonly experience at 
least one neuropsychiatric symptom. Approximately 50% of patients with dementia 
experienced at least one neuropsychiatric symptom in a large population-based study 
(Peters et al., 2015) but prevalence rates were closer to 80-90% in another study 
(Nowrangi, Lyketsos, & Rosenberg, 2015). 
Certain neuropsychiatric symptoms, such as depression, anxiety, apathy, and 
irritability, tend to be especially common in individuals with MCI and AD dementia. In 
a review of the literature, Apostolova and Cummings (2008) found that depression, 
apathy, and anxiety were consistently among the top four neuropsychiatric symptoms 
most frequently experienced by patients with MCI, with other common symptoms 
including irritability and agitation. Similarly, Geda and colleagues (2008) found that 
apathy, agitation, anxiety, irritability, and depression were approximately two to five 
times more prevalent among patients with MCI than older adults with normal cognition.  
Apathy seems to increase with worsening AD severity so that it may be the most 
common neuropsychiatric symptom in AD dementia (Apostolova & Cummings, 2008). 
Drijgers and colleagues (2011) reported higher rates of apathy in patients with dementia 
(35.3%) versus patients with MCI (25.8%). However, Ramakers and colleagues (2010) 
reported that 70% of their sample with MCI endorsed symptoms of apathy.  
Emotional (e.g., agitation, depression, anxiety) and behavioral (e.g., apathy, 
euphoria, disinhibition) symptoms increase with advancing dementia severity and 
remain more common than psychotic symptoms. According to a study by Canevelli and 
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colleagues (2013), among participants with mild AD (CDR = 1), approximately 46% had 
emotional and/or behavioral symptoms, whereas approximately 60% of older adults with 
moderate to severe AD (CDR = 2 or 3) had these symptoms. Gallagher and colleagues 
(2010) suggest that anxiety may be the most common neuropsychiatric symptom in MCI 
(52% of their MCI sample), but affective disturbances (37%) and aggression (32%) were 
also relatively common. In this study, other neuropsychiatric symptoms were less 
common but still present, including 23% of the sample with purposeless activity and 
12% of the sample with delusions. Similarly, in the study by Canevelli and colleagues 
(2013), psychotic symptoms were less common than emotional or behavioral symptoms 
but still present and increased with dementia severity. In this study, approximately 12% 
of older adults with mild AD (CDR = 1) had psychotic symptoms, whereas almost 26% 
of older adults with moderate to severe AD (CDR = 2 or 3) had psychotic symptoms.  
Neuropsychiatric symptoms and risk for Alzheimer’s disease. 
Neuropsychiatric symptoms are associated with higher risk for AD dementia (Rosenberg 
et al., 2013). Several studies have confirmed a link between depression and increased 
risk of developing dementia due to AD (e.g., Apostolova & Cummings, 2008; Brodaty et 
al., 2012; Byers & Yaffe, 2011; Ownby, Crocco, Acevedo, John, & Loewenstein, 2006). 
Indeed, depressive symptoms increase prior to a diagnosis of AD (Gaugler et al., 2014). 
Both the presence and severity of depressive symptoms in MCI are independent 
predictors of progression to AD dementia (Van der Mussele et al., 2014). It should be 
noted that it is still controversial whether depression represents a risk factor for dementia 
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or prodromal symptoms of dementia. Regardless of the etiology, though, it has been 
established that symptoms of depression are linked to higher risk of AD. 
Neuropsychiatric symptoms also may predict conversion to MCI and dementia. 
Symptoms of anxiety in cognitively healthy individuals predicted conversion to MCI 
over a two-year period (Brodaty et al., 2012). Furthermore, individuals who convert 
from MCI to AD dementia seem to experience more symptoms of anxiety compared to 
individuals who remain stable in MCI (Gallagher et al., 2010). Specifically, Gallagher 
and colleagues (2010) found that the combination of anxiety about future events and 
purposeless activity (e.g., pacing, repetitively putting on and taking off clothing) 
significantly predicted conversion from MCI to AD. However, this predictive 
relationship was not independent of performance on a brief neuropsychological battery 
(CAMCOG), so these neuropsychiatric symptoms actually may serve as a proxy of 
clinical severity rather than independent predictors. Furthermore, it is noteworthy that 
these neuropsychiatric symptoms were rated by informants rather than the participants 
themselves, so they represented behaviors that had become noticeable to observers.  
Banks and colleagues (2014) also studied how neuropsychiatric symptoms may 
predict conversion to AD. Of their sample of 644 cognitively healthy older adults 
participating in the Alzheimer’s Disease Cooperative Study Prevention Instrument 
Project, participant-reported presence of neuropsychiatric symptoms at baseline 
predicted conversion to MCI or AD over a four-year period. Those who converted 
reported higher levels of anxiety at baseline than those who did not convert. There were 
no differences in participant-reported levels of depression, apathy, or irritability at 
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baseline between those who progressed and those who did not. Among those participants 
who later converted to MCI or AD, their study partners more frequently reported 
symptoms of anxiety but also depression. Interestingly, however, total neuropsychiatric 
symptoms reported by partners at baseline did not predict decline to MCI or AD. As 
participants progressed to MCI or AD over time, partners reported increased levels of 
neuropsychiatric problems overall and anxiety and apathy specifically. These findings 
suggest that self-reported symptoms of anxiety and depression among cognitively 
healthy older adults may be risk factors of later conversion to MCI or AD. Caregivers 
are able to detect and report increasing levels of anxiety and apathy as patients’ 
cognition worsens.  
Other studies have found a link between apathy and increased risk of developing 
AD dementia (Apostolova & Cummings, 2008). A longitudinal study by Copeland and 
colleagues (2003) found higher rates of apathy at baseline among individuals who 
converted from normal aging to AD over a three-year period (27%) compared to control 
subjects who remained stable and cognitively normal (3%). Similarly, Balsis, Carpenter, 
and Storandt (2005) described increases in apathy prior to a diagnosis of AD for 24% of 
their sample who converted to dementia. Twenty-one percent of their sample with 
preclinical AD experienced increases in apathy prior to death.  
Another recent study by Palmer and colleagues (2011) showed that symptoms of 
apathy were a strong predictor of conversion from amnestic MCI to AD; in fact, patients 
who had clinically relevant symptoms of apathy (i.e., an Apathy score of at least 2 on the 
Neuropsychiatric Inventory) in MCI had a fourfold chance of progressing to AD relative 
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to patients without symptoms of apathy. This same study did not find that depressive 
symptoms in MCI increased risk of converting to AD over a four-year period, which 
suggests that the presence of apathy in MCI may be a critical marker of AD risk, 
independent of depressive symptoms.  
Finally, agitation has been suggested as a risk factor for AD. Copeland and 
colleagues (2003) reported higher rates of agitation at baseline among individuals who 
converted from MCI to AD over a three-year period (36%) relative to individuals who 
remained stable in MCI (18%) and individuals who remained cognitively normal over 
this period (6%). A separate study found that the severity of verbal agitation, in 
particular, was associated with higher risk of converting from MCI to AD (Van der 
Mussele et al., 2014). 
Neuropsychiatric symptoms and cognitive deficits. In addition to elevating 
risk of diagnostic conversion, neuropsychiatric symptoms are associated with specific 
cognitive deficits. The presence of neuropsychiatric symptoms is associated with worse 
executive functioning, attention, and global cognition among older adults with normal 
cognition or MCI (Brodaty et al., 2012). Brodaty and colleagues also found several 
associations between specific neuropsychiatric symptoms and neuropsychological 
impairment. Depression was linked to impaired executive function; anxiety to impaired 
attention/processing speed, memory, visuospatial abilities, and global cognition; 
agitation to impaired memory, visuospatial abilities, and global cognition; and apathy to 
impaired visuospatial skills and global cognition. In a separate study, apathy was linked 
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with poorer executive functioning, particularly psychomotor speed in MCI and verbal 
fluency in MCI and AD (Drijgers et al., 2011).  
In terms of longitudinal outcome, neuropsychiatric symptoms may accelerate 
cognitive decline. A few studies have analyzed this issue in samples of older adults with 
normal cognition, MCI, and AD. Among older adults without cognitive impairment, 
depressive symptoms may hasten decline in global cognition and episodic memory 
(Panza et al., 2009). Baseline anxiety and agitation were associated with declines in 
executive functions and language, respectively, over a two-year period for individuals 
with either MCI or normal cognition (Brodaty et al., 2012). Increases in euphoria, 
aberrant motor behavior, problematic eating behaviors, and worsening sleep quality have 
been linked to cognitive decline among individuals with MCI (Pocnet et al., 2015). 
Among individuals with moderate to severe AD, the presence of any behavioral 
symptoms (i.e., apathy, disinhibition, euphoria, and/or aberrant motor behavior) has been 
associated with more rapid cognitive decline (Canevelli et al., 2013). Furthermore, 
results from the Cache County Dementia Progression Study, a large population-based 
study, suggest that psychosis (i.e., delusions, hallucinations) and agitation/aggression are 
associated with faster progression to severe AD (Peters et al., 2015). Psychosis, affective 
symptoms (i.e., depression, anxiety, irritability), and agitation also were associated with 
earlier death in this study. Although only a handful of studies have examined the 
relationship between neuropsychiatric symptoms and cognitive change in elderly 
samples, it appears that neuropsychiatric symptoms are linked to more rapid 
deterioration of global and specific cognitive functions.  
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In sum, neuropsychiatric symptoms become more prevalent as cognition 
declines, particularly depression, apathy, anxiety, irritability, and agitation. These 
neuropsychiatric symptoms increase risk of converting from milder forms of cognitive 
impairment to dementia due to AD. Neuropsychiatric disturbances have been linked to 
poorer neuropsychological performance on executive, attentional, and global cognitive 
measures and may actually hasten cognitive deterioration over time. More research is 
needed to better understand the influence of neuropsychiatric symptoms on cognitive 
dysfunction in AD, especially over time and for important subgroups of patients, such as 
women and men. Neuropsychiatric symptoms often vary by men and women, so it may 
be important to examine their influence on cognitive functions for each gender. 
Furthermore, many of these aforementioned studies included gender as a covariate or 
confounding variable, rather than examining whether the relationship between 
neuropsychiatric symptoms and cognitive dysfunction in AD may vary across gender. 
This is an important empirical issue, especially considering the gender imbalance in AD. 
Gender Gap in Alzheimer’s Disease 
There is a critical gender gap that exists in AD, with more women affected by the 
disease than men. Almost two-thirds of individuals with AD in the United States are 
women (Alzheimer’s Association, 2015; Carter, Resnick, Mallampalli, & Kalbarczyk, 
2012) and numerous studies have confirmed higher prevalence of AD in women than 
men (e.g., Brookmeyer et al., 2007; Plassman et al., 2007; Tschanz et al., 2011; Zhang et 
al., 1990). Prevalence rates of AD tend not to be adjusted to account for differences in 
base rates of women and men in the general older adult population. Among the broader 
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population of adults 65 years and older, approximately 56% are women, but after the age 
of 85 years women outnumber men almost 2 to 1 (Administration on Aging, 
Administration for Community Living, & U.S. Department of Health and Human 
Services, 2015).  
Only a couple studies have analyzed prevalence rates of AD within women and 
men separately to account for this base rate difference. In a Chinese sample of older 
adults with AD and other dementias, prevalence rates were significantly higher in 
women than men (Zhang et al., 1990). In the Aging, Demographics, and Memory Study, 
a population-based study of older Americans, 11.48% of women and 7.05% of men over 
the age of 71 years had AD (Plassman et al., 2007). These findings suggest that even 
after controlling for differences in the proportion of women to men in the older adult 
population, women are more likely to have AD. 
It also is useful to consider gender differences in incidence rates of AD, or the 
number of new cases of AD that are diagnosed within a given time period. Gender 
differences in incidence rates contrast women’s risk of developing AD compared to 
men’s risk, whereas gender differences in prevalence rates describe the relative 
proportion of women to men who have AD at a given time. Although many studies have 
found similar incidence rates of AD in women and men (e.g., Bachman et al., 1993; 
Barnes et al., 2003; Ganguli, Dodge, Chen, Belle, & DeKosky, 2000; Hebert, Scherr, 
McCann, Beckett, & Evans, 2001; Mielke, Vemuri, & Rocca, 2014), other studies have 
suggested that women are actually at greater risk of developing AD. In De Deyn and 
colleagues’ (2011) study of Belgian older adults between the ages of 75 to 80 years, 
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incidence rates of dementia over a three-year period were almost 1.5 times greater for 
women (41.53 per 1000 women) relative to men (28.85 per 1000 men). Although a large 
proportion of this sample converted to AD, many participants did convert to other forms 
of dementia. Studies specific to AD incidence rates have confirmed increased 
vulnerability to the disease for women. In an early study of sex-specific incidence rates 
of AD between the ages of 75 to 85 years (Aronson et al., 1990), women were 2.7 times 
as likely as men to develop AD. In a meta-analysis conducted by Gao and colleagues 
(1998), women had an incidence rate of AD that was 1.56 times the incidence rate for 
men. 
Fratiglioni and colleagues (1997, 2000) found that among European samples of 
older adults, incidence rates were significantly higher for women than men at every age. 
Furthermore, incidence rates continued to increase for women past the age of 85, 
whereas incidence rates plateaued for men after the age of 85. Ruitenberg and colleagues 
(2001) examined sex differences in AD incidence rates in a large, longitudinal, 
population-based study of adults 55 years and older in the Netherlands. Incidence rates 
were similar for men and women until the age of 90 years, after which women’s 
incidence rates continued to increase whereas men’s incidence rates declined. These 
studies suggest that women not only have higher incidence rates of AD than men, but 
that this gender gap becomes more pronounced late in life, after the approximate ages of 
85 to 90 years. 
Data from the Cache County Study, a large longitudinal study of older adults 
between the ages of 65 to 100-plus years, suggest a nonlinear relationship between age 
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and incidence that varies slightly across gender. Controlling for education and APOE ε4 
genetic risk, Zandi and colleagues (2002) found that men and women had similar 
incidence rates of AD between the ages of 65 to 80, after which women were 
approximately twice as likely as men to develop AD. In both men and women, incidence 
rates continued to increase up to a certain age and then decelerated thereafter (Miech et 
al., 2002). This finding is consistent with other studies that have found a deceleration of 
the increase in incidence rates with advancing age (Gao et al., 1998). However, Miech 
and colleagues found a significant gender difference in when this deceleration occurred. 
For men, the critical age was 93 years, but incidence rates did not decline for women 
until after the age of 97 years. Overall, these studies showed that women’s risk of AD is 
substantially higher than men’s after the age of 85, and that although incidence rates for 
both sexes may decelerate late in life, this deceleration happens later for women than for 
men. 
Gender differences in cognition: Cross-sectional findings. In addition to sex 
differences in prevalence and incidence rates of AD, there are gender differences in the 
cognitive profile of AD. The literature on cognitive differences between men and women 
with AD is relatively sparse, but it does suggest that women tend to show worse 
cognitive deficits than men.  
Among healthy adults, women tend to slightly outperform men on tasks of verbal 
ability (including verbal episodic memory and verbal fluency), whereas men tend to 
have better visuospatial abilities (de Frias, Nilsson, & Herlitz, 2006; Voyer, Voyer, & 
Bryden, 1995; Weiss, Kemmler, Desenhammer, Fleischhacker, & Delazer, 2003). In 
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healthy older adults, men seem to retain their visuospatial advantage (Millet et al., 2009) 
and women seem to retain their advantage on tests of verbal memory. Barnes and 
colleagues (2003) examined cross-sectional sex differences in cognitive abilities in 
participants from the Religious Orders Study who were cognitively healthy and free of 
dementia at baseline. They found that women performed better than men on tasks of 
verbal episodic memory and perceptual speed, but worse than men on semantic memory 
(including tasks of verbal fluency, naming, and vocabulary). Women and men had 
equivalent performances on working memory, visuoperceptual skills, and nonverbal 
reasoning. Similarly, Munro and colleagues (2012) found that women performed better 
than men on tasks of psychomotor speed and verbal episodic memory. However, in this 
study, women performed worse than men on tasks of visuoconstruction and visual 
perception and equivalent to men on tests of verbal fluency and executive functioning. 
The reliable pattern of stronger verbal skills in cognitively healthy women seems 
to change with the development of AD. Pusswald and colleagues (2015) found 
consistent deficits in verbal memory for women with AD relative to men with AD, but 
no sex differences in nonverbal memory or executive functions. This sex difference in 
verbal memory remained even after controlling for dementia stage and educational 
attainment. Chapman and colleagues (2011) also found that men with AD outperformed 
women with AD for verbal episodic learning and memory, although among healthy 
control participants, women performed better than men on these tasks.  
Beinhoff and colleagues (2008) studied sex differences in verbal and visuospatial 
episodic memory among a sample of German participants diagnosed with AD dementia, 
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MCI, or healthy controls. Although women performed better than men on tasks of verbal 
episodic memory in the healthy control and MCI groups, there was no sex difference in 
verbal episodic memory in the AD condition. Men performed better than women in 
visuospatial episodic memory in the AD group, but there were no sex differences in 
visuospatial memory in the MCI or healthy control groups. Furthermore, the authors 
found that men with MCI and AD had a distinct pattern of visuospatial delayed recall 
that was stronger than verbal delayed recall. In contrast, women performed equally poor 
for both types of memory (verbal vs. visuospatial). There were no gender differences in 
any of the diagnostic groups on cognitive tasks of verbal fluency and naming. Again, 
this pattern of sex differences was independent of dementia severity (measured by the 
MMSE) and intelligence (measured by a German vocabulary test). 
 These studies suggest that women lose their verbal advantage with the 
development of AD. Men, on the other hand, may retain their visuospatial advantage and 
even performed better than women on verbal tasks in some studies. Other studies 
suggest that there are no sex differences in certain cognitive abilities in AD, but overall 
the findings are mixed and somewhat inconsistent. To analyze trends across various 
samples, Irvine and colleagues (2012) published a meta-analysis of 15 studies of AD 
patients. Their results revealed small but consistent deficits across all cognitive domains 
examined for women relative to men. These cognitive domains included verbal, 
visuospatial, memory, semantic, and nonsemantic abilities, with effect sizes ranging 
from d = 0.14 to d = 0.27. Males had an advantage and performed significantly better 
than female participants in all these cognitive domains. This pattern was independent of 
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global dementia severity (measured by the MMSE), age, or educational attainment. 
Although there may be inconsistencies in patterns of sex differences between individual 
studies, this meta-analysis argues for a distinct female deficit in cognitive performance 
among individuals with AD. 
 Gender differences in cognition: Longitudinal findings. It is also important to 
consider how cognitive functions change over time for women compared to men. Not 
enough research has analyzed this issue, and among the studies that do exist, there are 
inconsistent findings regarding sex differences in cognitive trajectories.  
Even among older adults who are cognitively healthy, there is not a clear 
consensus of how men and women experience cognitive change. A systematic review of 
13 studies of healthy older adults (Ferreira, Santos, Ferri, & Galduroz, 2014) did not find 
evidence of sex differences in rates of cognitive decline between the ages of 60-80 years. 
Rather, the authors indicated that age was the biggest predictor of rate of cognitive 
change, with decline becoming faster in older individuals. Barnes et al. (2003) also 
found that men and women who were cognitively healthy at baseline had similar rates of 
cognitive change over an eight-year period. These findings are in contrast with a large 
epidemiological study of 6476 healthy older adults born before 1924 (Karlamangla et al., 
2009), which found that global cognitive decline was faster in women than men across a 
nine-year period. Proust-Lima and colleagues (2009) also found slightly steeper 
cognitive decline in healthy older females relative to healthy older men. 
For individuals on the AD spectrum, we simply do not have enough information 
about sex differences in cognitive trajectories, but preliminary evidence suggests that 
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women experience steeper cognitive decline than men. Holland and colleagues (2013) 
found that women with MCI had faster rates of decline over a 36-month period than men 
on two global measures of severity, the CDR-SB and ADAS-Cog. Men and women with 
AD dementia declined at similar rates on these global measures. In contrast, Tschanz and 
colleagues (2011) found that in a sample of individuals diagnosed with AD, females 
declined faster than men on the MMSE, a measure of global cognitive dysfunction. The 
former study utilized clinical trial data from the Alzheimer’s Disease Neuroimaging 
Initiative, whereas the latter study used population-based data, which may explain the 
discrepant findings. 
There are no studies that have examined sex differences in specific areas of 
cognitive change (in contrast to change on measures of global severity) among 
individuals with MCI or AD. Given the worse cognitive performance that women 
demonstrate in cross-sectional studies, it is critical to analyze how cognitive functions 
change over time in women versus men.  
In sum, we do not yet fully understand just how AD influences cognitive 
functions in women relative to men. There are few studies that consider either cross-
sectional or longitudinal sex differences in cognitive abilities in an AD sample. We need 
more information about how a broad range of cognitive functions change across the 
course of AD to fill in our understanding of this important issue. 
It is also important to consider what drives these sex differences in cognition in 
AD. Does AD affect women differently than men? Do women’s cognitive abilities 
deteriorate at a faster rate than men’s? On the other hand, perhaps the measures 
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themselves assess cognitive abilities differently for men than for women on the AD 
spectrum. These issues remain unclear. It is essential to examine whether there might be 
a gender bias in the tests that would explain why women perform worse than men, or 
whether there are other factors that might account for these sex differences in cognition. 
Furthermore, once we better understand this issue at the cross-sectional level, it is 
critical to understand how cognitive functions deteriorate over time in women relative to 
men with AD. 
Explaining the Gender Gap in Alzheimer’s Disease 
 There are several theories about why women seem to be more vulnerable to AD 
than men. Traditionally, the gender gap in prevalence rates has been attributed to 
women’s longer life expectancy, since advancing age is the greatest risk factor for 
developing AD (Hebert et al., 2001; Plassman et al., 2007). There is also some evidence 
that men are more likely than women to die of cardiovascular disease in mid-life, so 
those men who survive into late life may have better cardiovascular health than women 
and thus lower risk of dementia (Chene et al., 2013). Among those who do develop AD, 
studies have found that men have higher mortality rates and more medical comorbidities 
relative to women (Gambassi et al., 1999; Sinforiani et al., 2010), so clinical outcomes, 
particularly survival duration, may vary between sexes. These factors may partially 
explain gender differences in prevalence rates. 
It is essential also to consider why women may have a higher risk of developing 
AD (i.e., higher incidence rates). In the current older adult cohort, men are more likely 
than women to have higher cognitive reserve (e.g., greater educational and occupational 
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attainment), which has been shown to reduce risk for AD (Stern, 2012). There is also 
evidence that apolipoprotein E, a well-known genetic risk factor for AD, actually puts 
women at higher risk than men for developing AD (Damoiseaux et al., 2012; Ungar, 
Altmann, & Greicius, 2014). 
In addition, changes in estrogen may play a key role in the gender gap, 
considering that women experience a dramatic decline in estrogen levels at menopause. 
Estrogen has been shown to have a neuroprotective effect against damage to the brain 
caused by beta-amyloid and tau (Dye, Miller, Singer, & Levine, 2012). Declines in 
estrogen due to menopause have been linked to risk of AD (Dye et al., 2012; Paganini-
Hill & Henderson, 1994; Zandi et al., 2002) and cognitive impairment (Rocca, 
Grossardt, & Maragnore, 2008b). Interestingly, reductions in estrogen levels after 
bilateral oophorectomy (i.e., surgical removal of both ovaries) have also been linked to 
higher long-term risk of depressive and anxious symptoms compared to women who 
experienced natural menopause (Rocca et al., 2008a), which suggests that there may be a 
relationship between estrogen and affective symptoms. 
While these factors contribute to the gender gap in AD, they may not completely 
explain women’s vulnerability to AD, both in terms of higher incidence rates and worse 
cognitive performance. For example, Irvine and colleagues (2012) found that women 
with AD had consistent cognitive deficits relative to men with AD even after controlling 
for educational attainment, an indicator of cognitive reserve. Changes in estrogen are 
clearly associated with risk of AD, but it is uncertain whether these hormonal changes 
directly cause neurocognitive impairment or may be mediated by another mechanism 
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(e.g., affective symptoms). There is likely a complex web of interacting factors that drive 
gender differences in the development and clinical expression of AD. There are likely 
other factors beyond those already discussed that place women at greater risk for AD-
associated deteriorations. 
The potential contribution of neuropsychiatric symptoms to the gender gap in AD 
has not been considered carefully. Women are far more likely than men to experience 
affective disorders like depression and anxiety throughout their lifetime (Leach, 
Christensen, Mackinnon, Windsor, & Butterworth, 2008; McLean & Anderson, 2009; 
Seeman, 1997). In fact, women are approximately twice as likely as men to suffer from 
depression or generalized anxiety disorders (Kessler, 2003; Kessler, McGonagle, Swartz, 
Blazer, & Nelson, 1993; Vesga-Lopez et al., 2008). Depressed older adults are also more 
likely to be female, both in the absence of overt cognitive impairment (Apostolova & 
Cummings, 2008; Luppa et al., 2012) and in MCI and dementia (Cerejeira, Lagarto, & 
Mukaetova-Ladinska, 2012; Van der Mussele et al., 2014). Self-reported sleep problems 
are linked with higher risk of developing AD in men (Benedict et al., 2014). In a recent 
study by Brodaty and colleagues (2015), women were more likely to be depressed 
whereas men were more likely to experience apathy, agitation, disinhibition, irritability, 
and delusions–although it should be noted that this was within a mixed sample of adults 
with various types of dementia. In a related study of nursing home patients with mixed 
forms of dementia, men were more likely to exhibit apathy while women were more 
likely to experience depression and anxiety (Zuidema, de Jonghe, Verhey, & Koopmans, 
2009). In a large study of nursing home residents with AD (Buchanan, Wang, Ju, & 
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Graber, 2004), women were more likely to exhibit depressive and anxious behaviors, 
whereas men were likely to wander and demonstrate repetitive movements, like pacing 
and fidgeting.  
In general, research is scarce that examines sex differences in neuropsychiatric 
symptoms experienced by individuals on the AD spectrum. We need this information, 
not only to better understand how men and women are affected by emotional/behavioral 
symptoms as part of AD but also to examine whether neuropsychiatric symptoms may 
contribute to the overall gender gap in AD (Li & Singh, 2014). Women’s elevated 
lifetime risk of affective symptoms such as depression and anxiety may contribute to an 
increased vulnerability to AD. For example, depression has been linked to cerebral 
atrophy and glucose hypermetabolism in numerous cortical regions in older adults 
(Smith et al., 2009), including hippocampal volume loss (Naismith, Norrie, 
Mowszowski, & Hickie, 2012). Psychiatric symptoms could cause an accumulation of 
detrimental effects over time. Because women are at higher risk of these affective 
symptoms, then this psychiatric-related neurological damage could mediate the gender 
gap in the development and clinical expression of AD. However, this hypothesis needs 
to be analyzed. 
Aims of the Proposed Research 
Given these important, unanswered questions about the relationships among 
cognitive dysfunction, gender, and neuropsychiatric symptoms in AD, the current study 
had the following goals within four broad aims: 
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Aim 1: Model cognitive dysfunction in AD. Cross-sectional and longitudinal 
models of AD-associated cognitive dysfunction are needed to improve our 
understanding of how cognitive functions are impaired and decline across the course of 
the disease. 
Goal A: Develop a cross-sectional model of AD-associated cognitive 
dysfunction. This study modeled the relative impairment of cognitive functions across 
the continuum of AD-associated cognitive dysfunction based on participants’ 
performance at baseline (i.e., their first evaluation). Cognitive functions that were 
examined included memory, language, visuospatial abilities, and executive 
functions/processing speed (measured by neuropsychological assessment). The research 
produced statistical models that describe the relationship between neuropsychological 
tests/indicators and latent variables of AD-associated cognitive dysfunction (i.e., latent 
variables of memory, language, visuospatial abilities, executive/processing speed, and 
overall cognitive dysfunction).  
Goal B: Model longitudinal change in AD-associated cognitive dysfunction. 
This provides important information about the relative rate at which specific cognitive 
functions change and become impaired over time along the AD continuum. This 
information will refine what we know about the neuropsychological profile of AD. 
These AD-associated cognitive trajectories were compared to patterns of cognitive 
change in the control subjects. 
Aim 2: Analyze gender differences in AD-associated cognitive dysfunction. 
There is mixed information about whether women and men experience different 
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neuropsychological profiles of AD. This needs to be analyzed cross-sectionally and 
longitudinally for a range of cognitive functions. 
Goal A: Analyze cross-sectional gender differences in AD-associated cognitive 
dysfunction. The research examined the generalizability of the baseline measurement 
model of cognitive dysfunction across gender. Sex differences in this baseline model 
would suggest differences in structure, sensitivity, or relative impairment of cognitive 
markers between men and women. Results were compared between participants with a 
diagnosis of AD within the first two years of their ADNI enrollment and a non-demented 
sample.  
Goal B: Analyze gender differences in AD-associated cognitive trajectories. 
The study examined whether there were gender differences in longitudinal cognitive 
change. This sheds light on whether men and women experience similar trajectories of 
cognitive decline in AD or whether there are key gender differences in the progression 
of cognitive deterioration. Again, results were compared between the AD sample and the 
non-demented sample. 
Aim 3: Examine whether neuropsychiatric symptoms mediate potential 
effects of gender on AD-associated cognitive dysfunction. Neuropsychiatric 
symptoms increase with dementia severity, have been associated with higher risk for AD 
and faster cognitive deterioration, and often differ in prevalence between women and 
men. It may be that neuropsychiatric symptoms contribute to the overall gender gap in 
AD, but this needs to be analyzed. 
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Goal A: Examine whether neuropsychiatric symptoms mediate potential 
gender differences in cross-sectional AD-associated cognitive dysfunction. The study 
examined whether neuropsychiatric symptoms might explain any cross-sectional gender 
differences in AD-associated cognitive dysfunction.  
Goal B: Examine whether neuropsychiatric symptoms mediate potential 
gender differences in AD-associated cognitive change. The research also examined 
whether neuropsychiatric symptoms were a mechanism for any gender differences in 
longitudinal trajectories of AD-associated cognitive dysfunction. 
Aim 4: Analyze whether gender or neuropsychiatric symptoms predict odds 
of conversion to AD. Finally, the research examined conversion from non-demented 
aging to AD, an important medical milestone. Specifically, the research analyzed 
whether conversion rates differed by gender and/or neuropsychiatric symptoms. Are 
women more or less likely to convert from MCI to AD than men? Does the presence or 
severity of neuropsychiatric symptoms influence likelihood of conversion? This aim 
provided key information about whether gender and/or neuropsychiatric symptoms 
predicted likelihood of converting from healthy aging or MCI to AD.  
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METHOD 
 The Alzheimer’s Disease Neuroimaging Initiative (ADNI) database was 
analyzed for this study. ADNI was launched in 2003 by the National Institute on Aging, 
the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug 
Administration, private pharmaceutical companies and non-profit organizations as a 
public-private partnership. The initial phase, ADNI1, was followed by two extensions, 
ADNI-GO and ADNI2. To date, ADNI has recruited over 1600 adults, ages 55 to 90 
years, from across the United States to participate in the research. These participants 
represent the continuum of AD, from cognitively normal individuals to those with 
clinical diagnoses of MCI and AD. Participants are followed longitudinally and 
participate in comprehensive evaluations, including thorough neuropsychological and 
neuropsychiatric assessment. The ADNI database provided a unique opportunity to 
analyze a wide spectrum of cognitive and neuropsychiatric functions–key disease-related 
variables–for a large sample of individuals who are followed longitudinally. Because of 
this, the ADNI database was ideal for analyzing the questions for the current research. 
Participants 
 ADNI has enrolled participants that represent a wide range of diagnoses along 
the AD spectrum, including normal aging, subjective memory concerns, MCI, and AD. 
According to ADNI protocol, cognitively normal (CN) participants serve as the controls 
and show no signs of MCI, dementia, or significant depression. CN participants have 
normal cognition (defined as CDR = 0, MMSE between 24-30, and WMS-R Logical 
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Memory II subscale score above education-adjusted cutoffs) and neither the participants 
nor their study partners report memory concerns.  
Beginning in ADNI2, participants with significant memory concerns (SMC) 
were enrolled. SMC participants have normal cognition (defined the same as for CN 
participants), but there is significant concern about memory (either reported by the 
participant, study partner, or clinician) coupled with a significant memory concern based 
on the Cognitive Change Index, a self-report scale.  
MCI participants have been enrolled since ADNI1, but in ADNI-GO and ADNI2, 
MCI participants were defined as either having early MCI or late MCI. Overall for an 
MCI diagnosis, subjects must have a subjective memory concern and exhibit significant 
amnestic dysfunction (defined by CDR = 0.5 plus an abnormal score on the WMS-R 
Logical Memory II subscale). However, MCI subjects have sufficiently preserved 
functional abilities and global cognition (MMSE score between 24-30), such that they do 
not meet criteria for AD. The determination of early MCI versus late MCI is based on 
severity of impairment on the WMS-R Logical Memory II subscale, a measure of 
delayed recall for auditory information presented in story format.  
Participants were diagnosed with AD if they met National Institute of 
Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and 
Related Disorders Association (NINCDS/ADRDA) criteria for probable AD (McKhann 
et al., 1984). At time of ADNI diagnosis, AD participants demonstrated deficits in their 
global cognition (based on MMSE scores between 20-26 plus CDR scores of 0.5 or 1), 
abnormal memory functioning (based on scores on the WMS-R Logical Memory II 
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subscale), and significant concerns with memory (reported by the participant, study 
partner, or clinician).  
For the current research study, participants were selected from across all three 
ADNI phases, ADNI1, ADNI-GO, and ADNI2. At the initial baseline appointment, 
1662 participants had completed all 15 cognitive tests of interest for the present study. 
Of these 1662 participants, 749 were female (45%) and 913 were male (55%). 
Participants ranged in age from 48 to 91 years old (M = 73.81, SD = 7.18 years) and 
were highly educated (M = 15.94, SD = 2.83 years). The majority of participants 
identified their race as White/Caucasian (n = 1537). Approximately one-third had a 
diagnosis of either CN or SMC (N = 511, 31%), half had a diagnosis of MCI (N = 852, 
51%), and the remainder had a diagnosis of AD (N = 299, 18%).  
Due to attritional factors and differences in timing of ADNI enrollment, the 
sample size decreased at subsequent follow-up visits (see Table 1), with notable drop-off 
after month 24. Across all time-points, males made up over half of the sample, and 
percentage of participants with AD did not exceed one-quarter. Although the sample size 
decreased, the sample characteristics did not change significantly across time points. 
We used this sample of 1662 participants to maximize power for estimating the 
cross-sectional, statistical models of AD-associated cognitive dysfunction (Aim 1a). For 
the other analyses, we used a slightly smaller sample of 1054 participants who had 
completed neuropsychological testing at baseline, month 12, and month 24 (see Table 2). 
This sample did not significantly differ from the larger baseline sample of 1662 
participants in terms of age, education, proportion of females, or diagnostic breakdown
  34 
Table 1. Longitudinal demographic statistics for all participants with cognitive data. 
Note. Percentages may not add to 100% due to rounding. CN = cognitively normal. SMC = subjective memory concerns. MCI 
































Baseline 1662 73.83 7.15  15.94 2.83  749 (45%) 913 (55%)  511 (31%) 852 (51%) 299 (18%) 
Month 6 1543 73.85 7.06  15.96 2.83  691 (45%) 852 (55%)  486 (32%) 748 (49%) 309 (20%) 
Month 12 1390 73.89 7.08  15.99 2.80  605 (44%) 785 (56%)  415 (30%) 660 (48%) 315 (23%) 
Month 18 312 74.58 7.20  15.84 2.92  110 (35%) 202 (65%)  10 (3%) 217 (70%) 84 (27%) 
Month 24 1100 73.72 7.04  16.09 2.77  481 (44%) 619 (56%)  370 (34%) 462 (42%) 268 (24%) 
Month 36 574 73.94 6.91  16.04 2.73  248 (43%) 326 (57%)  193 (34%) 258 (45%) 123 (21%) 
Month 48 283 74.62 6.50  16.05 2.78  116 (41%) 167 (59%)  107 (38%) 108 (38%) 67 (24%) 
Month 60 200 74.50 5.89  16.04 2.87  78 (39%) 122 (61%)  93 (47%) 65 (33%) 42 (21%) 
Month 72 204 74.83 5.97  15.95 2.89  83 (41%) 121 (59%)  95 (47%) 65 (32%) 44 (22%) 
Month 84 163 74.60 5.47  15.88 2.87  69 (42%) 94 (58%)  73 (45%) 63 (39%) 27 (17%) 
Month 96 92 74.53 5.73  16.07 2.89  32 (35%) 60 (65%)  43 (47%) 33 (36%) 16 (17%) 
  35 
Table 2. Demographic statistics for 1045 participants with cognitive data at baseline, month 12, and month 24. 
Note. Percentages may not add to 100% due to rounding. CN = cognitively normal. SMC = subjective memory concerns. MCI 


























Baseline 1045 73.71 7.04  16.11 2.76  455 (44%) 590 (57%)  339 (32%) 610 (58%) 96 (9%) 
Month 12 1045 -- --  -- --  -- --  353 (34%) 532 (51%) 160 (15%) 
Month 24 1045 -- --  -- --  -- --  354 (34%) 442 (42%) 249 (24%) 
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Table 3. Diagnostic conversion rates relative to baseline diagnosis for men and women. 
 
Note. Conversion rates are relative to baseline diagnosis. Percentages represent percentage of relevant sample; that is, 
percentage of overall sample, percentage of females, or percentage of males. CN = cognitively normal. SMC = subjective 


























Baseline 1045 339 (32%) 610 (58%) 96 (9%)  -- -- --  -- -- 
Female 455 161 (35%) 252 (55%) 42 (9%)  -- -- --  -- -- 
Male 590 178 (30%) 358 (61%) 54 (9%)  -- -- --  -- -- 
Month 12 1045 330 (32%) 521 (50%) 94 (9%)  9 (1%) 66 (6%) --  23 (2%) 2 (0%) 
Female 455 157 (35%) 210 (46%) 42 (9%)  4 (1%) 27 (6%) --  15 (3%) -- 
Male 590 173 (29%) 311 (53%) 52 (9%)  5 (1%) 39 (7%) --  8 (1%) 2 (0%) 
Month 24 1045 321 (31%) 424 (41%) 94 (9%)  16 (2%) 153 (15%) 2 (0%)  33 (3%) 2 (0%) 
Female 455 153 (34%) 177 (39%) 41 (9%)  7 (2%) 60 (13%) 1 (0%)  15 (3%) 1 (0%) 
Male 590 168 (29%) 247 (42%) 53 (9%)  9 (2%) 93 (16%) 1 (0%)  18 (3%) 1 (0%) 
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at baseline. Of these 1054 participants, 455 were female (44%) and 590 were male 
(57%). The mean age was 73.71 years (SD = 7.04), and the sample was still highly 
educated (M = 16.11, SD = 2.76 years). At baseline, 339 had a diagnosis of either CN or 
SMC (32%), 610 had a diagnosis of MCI (58%), and 96 had a diagnosis of AD (9%). By 
month 24, almost one-quarter of the sample had a diagnosis of AD (N = 249, 24%). 
Between baseline and month 24, two of the participants with a baseline diagnosis of AD 
reverted to MCI, but 153 converted from MCI to AD and two converted from CN to AD 
(see Table 3). 
Neuropsychological Battery 
All ADNI participants completed a battery of cognitive testing at baseline and 
regular follow-up appointments. The schedule of testing varied slightly depending on 
whether their baseline diagnosis was AD, MCI, SMC, or CN. All participants were 
scheduled to complete follow-up cognitive testing at months 6, 12, and ongoing annual 
visits. The core ADNI neuropsychological battery that has been administered across all 
ADNI phases includes the following tests: the Alzheimer’s Disease Assessment Scale-
Cognitive (ADAS-Cog; Mohs, Rosen, & Davis, 1983), Boston Naming Test (Kaplan, 
Goodglass, & Weintraub, 1983), Category Fluency Test (adapted from the CERAD 
Verbal Fluency test; Morris et al., 1989), Clock Drawing Test (Goodglass & Kaplan, 
1983), Rey Auditory Verbal Learning Test (RAVLT; Rey, 1964), and Trail Making Test 
(Reitan, 1958; Reitan & Wolfson, 1985).  
The current research analyzed 15 indicators from these neuropsychological tests 
that assess memory, language, executive functions, processing speed, and visuospatial 
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abilities. The ADAS-Cog assesses a variety of cognitive abilities, including memory 
(e.g., Delayed Recall and Word Recognition subtests), language (e.g., Naming subtest), 
visuoconstruction (e.g., Construction subtest), and processing speed (e.g., Number 
Cancellation subtest). The Boston Naming Test measures confrontation naming abilities, 
or a participant’s ability to retrieve names for a series of 30 objects when presented with 
two-dimensional line drawings of those objects. The Category Fluency Test, a measure 
of verbal fluency, includes an Animals condition, in which participants are given one 
minute to generate as many names of animals as they can. The Clock Drawing Test is a 
measure of visuoconstruction abilities. There are two conditions: in the first “command” 
condition (Clock command), participants are asked to draw a clock with the hands set to 
a specified time, whereas in the second “copy” condition (Clock copy), participants are 
asked to copy a drawing of a clock that is provided to them. The RAVLT assesses 
immediate, delayed, and recognition aspects of verbal learning and memory; the present 
study examined list learning over five trials (RAVLT Learning), short-delay recall on 
trial 6, 30-minute delayed recall, and recognition memory after a 30-minute delay. 
Finally, the Trail Making Test measures psychomotor speed (Trail Making A) and 
executive functions (Trail Making B).  
Neuropsychiatric Assessment 
 The Neuropsychiatric Inventory (NPI; Cummings et al., 1994), a structured 
clinical interview, was administered to a study partner/caregiver who knew the 
participant well in order to assess the participant’s neuropsychiatric functioning. The 
NPI was developed to assess various forms of psychopathology in individuals with AD 
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and other dementias. The NPI measures a range of neuropsychiatric symptoms, 
including depression, anxiety, apathy, irritability, euphoria, agitation/aggression, 
delusions, hallucinations, disinhibition, aberrant motor behavior, disordered sleep and 
nighttime behaviors, and changes in appetite and eating. The study partner/caregiver was 
asked to indicate whether the participant had demonstrated these any of these 12 
behaviors in the previous four weeks. For any behavior that the caregiver indicated was 
present in the past four weeks, the caregiver was then asked to rate severity of the 
behavior, frequency of the behavior, and amount of distress that the behavior caused the 
caregiver. The full NPI has only been administered during the ADNI2 phase.  
 The NPI-Questionnaire (NPI-Q; Kaufer et al., 2000) is an abbreviated version of 
the NPI that has been administered throughout the entirety of ADNI. As with the full 
NPI, study partners/caregivers were administered screening questions and asked to 
indicate whether any of the 12 behaviors had been present in the participant over the past 
four weeks. If the study partner indicated “yes” to any of the screening questions, the 
study partner was then asked to evaluate severity of the behavior. Severity ratings were 
made on a 3-point scale, where 1 is Mild (“noticeable, but not a significant change”), 2 is 
Moderate (“significant, but not a dramatic change”), and 3 is Severe (“very marked or 
prominent, a dramatic change”). If the behavior was rated as not present in the past 
month, then the Severity rating was 0. All of the Severity ratings were summed to 
produce the Total NPI-Q score.  
Although the NPI-Q has been used throughout all ADNI phases, participants 
have either NPI or NPI-Q data at any given timepoint; no participants have data for both 
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scales. For example, of the 1045 participants with cognitive data at baseline, month 12, 
and month 24, 410 (39%) had NPI data while the other 635 (61%) had NPI-Q data at 
baseline. To increase statistical power and utilize the entire sample, an NPI severity 
composite score was created based on the severity ratings on the NPI and NPI-Q. This 
NPI severity composite score represents overall severity of neuropsychiatric symptoms 
for participants, regardless of whether they had NPI or NPI-Q data. This NPI severity 
composite score was used for all analyses. 
Statistical Analyses 
 Statistical analyses were conducted largely within item response theory (IRT; 
Embretson & Reise, 2000; Hambleton, Swaminathan, & Rogers, 1991; Samejima, 1969) 
and structural equation modeling (SEM; Brown, 2015; Little, 2013) frameworks. These 
frameworks statistically factor out measurement error to permit analysis of how 
observed data (e.g., test scores) relate to latent constructs, such as latent cognition and 
latent neuropsychiatric disturbance.  
IRT requires categorical data, whereas SEM can analyze continuous data. 
Because the neuropsychological indicators are continuous and spanned ranges of 5 (e.g., 
ADAS-Cog Naming) to 300 (e.g., Trail Making B), they were placed into categories for 
IRT analyses. The range of these variables was determined in the dataset at baseline 
evaluation. Values for each variable were then placed into five equal-width categories (0 
through 4) using SPSS interval binning procedures.  
As described below, repeated-measures ANOVAs were conducted for 
longitudinal analyses. Linear regressions were computed for mediation analyses, and 
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binary logistic regressions were conducted to examine whether gender or 
neuropsychiatric symptoms predicted odds of conversion to AD. 
 Aim 1, Goal A: Develop a cross-sectional model of AD-associated cognitive 
dysfunction. Confirmatory factor analysis (CFA) was conducted to analyze the structure 
of cognitive abilities. A second-order CFA model was hypothesized to fit the data, with 
a higher-order latent factor of global AD-associated cognitive dysfunction and four 
lower-order latent factors of discrete cognitive domains: memory, language, 
visuospatial, and executive/processing speed. The clustering of neuropsychological 
measures into these four lower-order cognitive domains and single higher-order factor 
was guided by test content and a previously published factor analysis of the ADNI1 
neuropsychological battery (Park et al., 2012). 
Within an IRT framework, Samejima’s graded response model (Samejima, 1969) 
was used to estimate each cognitive marker’s sensitivity or ability to measure latent AD-
associated cognitive dysfunction (i.e., the a parameter) and discriminate between degrees 
of latent cognitive dysfunction (i.e., the b parameter). This produced a model that placed 
each cognitive marker’s discriminative ability on a common scale so that they could be 
directly compared to one another. This enabled examination of how well and at what 
degree of disease severity different areas of cognitive dysfunction yielded information 
about AD. This cross-sectional model provided information both at the level of cognitive 
domains and at the level of specific tests. In other words, developing this model 
provided information about how the four cognitive domains (e.g., memory, language, 
visuospatial, executive/processing speed) related to one another across the continuum of 
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AD-associated cognitive dysfunction, but also about how specific tests (e.g., each of the 
memory tests examined) related to one another across this spectrum.  
 Aim 1, Goal B: Model longitudinal change in AD-associated cognitive 
dysfunction. Cognitive change between baseline, month 12, and month 24 was 
examined for all cognitive domains (i.e., memory, language, visuospatial, 
executive/processing speed, and global cognitive dysfunction). Repeated-measures 
ANOVAs were computed for each cognitive domain. Within-subjects polynomial 
contrasts were used to test linear versus quadratic rates of change from baseline to month 
12 and month 24. Because age and education are known correlates of cognitive 
performance (e.g., Ardila, Ostrosky-Solis, Rosselli, & Gomez, 2000; van Hooren et al., 
2007), they were entered as covariates in the models. In addition, clinical diagnostic 
status at month 24 was entered as a between-subjects factor. The diagnostic status 
variable represented whether the patient had a diagnosis of AD or was non-demented at 
month 24 of their ADNI enrollment. This binary variable was included as a moderating 
variable to test whether rate of cognitive change differed between an AD group and a 
non-demented group, as would be expected. Gender was also entered as a between-
subjects factor in this model to test whether rate of change differed by gender for Aim 
2B, described below. 
 Aim 2, Goal A: Analyze cross-sectional gender differences in AD-associated 
cognitive dysfunction. This goal was analyzed using an IRT framework. Differential 
item functioning (DIF) was used, which allows one to analyze whether items function 
differently or may be biased against one group compared to another. For the current 
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study, DIF techniques were harnessed to analyze whether the cross-sectional model of 
AD-associated cognitive dysfunction was equivalent in women and men, specifically 
whether any of the cognitive domains or 15 cognitive tests functioned significantly 
differently for women relative to men.  
  Aim 2, Goal B: Analyze gender differences in AD-associated cognitive 
trajectories. Potential gender differences were analyzed within the repeated-measures 
ANOVA models. Gender was entered as a between-subjects factor. This allowed us to 
test whether there was a main effect of gender on the average cognitive score across 
baseline, month 12, and month 24 for each cognitive domain. More interestingly, it 
enabled us to examine whether there was a significant time by gender interaction, which 
would suggest that women had a different pattern of cognitive change than men. 
Diagnostic status was also entered as a between-subjects factor to compare whether the 
effects of gender differed between the AD group and the non-demented group.  
 Aim 3, Goal A: Examine whether neuropsychiatric symptoms mediate 
potential gender differences in cross-sectional AD-associated cognitive dysfunction.  
We conducted a series of regressions (one set for each cognitive domain) according to 
the Baron and Kenny (1986) approach to test whether severity of neuropsychiatric 
symptoms mediated a gender effect on cognitive dysfunction. Age and education were 
entered as covariates in each of the steps. First, we analyzed whether gender 
significantly predicted cognitive dysfunction. Second, we examined whether gender 
predicted neuropsychiatric symptoms (i.e., the NPI severity composite). Third, we 
analyzed whether neuropsychiatric symptoms predicted cognitive dysfunction 
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controlling for gender. Fourth, we examined whether gender still significantly predicted 
cognitive dysfunction after controlling for neuropsychiatric symptoms. In order to 
demonstrate mediation, the effect of gender on cognitive dysfunction in step one would 
be significant, but it would become non-significant in step four after controlling for 
neuropsychiatric symptoms. These regressions testing for mediation were first conducted 
in the overall sample. They were then conducted in the AD sample and non-demented 
samples separately to examine whether diagnostic status served as a moderator for any 
mediation effect. 
 Aim 3, Goal B: Examine whether neuropsychiatric symptoms mediate 
potential gender differences in AD-associated cognitive change. To examine whether 
neuropsychiatric symptoms mediated any effects of gender on cognitive change, we re-
ran the repeated measures ANOVA models as described above, but entered the NPI 
severity composite score as a covariate. Again, gender and diagnostic status were 
entered as between-subjects factors, age and education were entered as covariates (in 
addition to the NPI severity composite score), and each latent cognitive score was 
entered as a dependent variable in turn. Conducting these repeated-measures ANOVAs 
allowed us to examine whether any significant effects of gender from previous analyses 
(aim 2, goal B) became non-significant after controlling for neuropsychiatric symptoms. 
 Aim 4: Analyze whether gender or neuropsychiatric symptoms predict odds 
of conversion to AD. A binary logistic regression was conducted to analyze whether 
gender or neuropsychiatric symptoms predicted odds of conversion to AD. In the model, 
a binary variable representing conversion from CN or MCI to AD (0 = no, 1 = yes) was 
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entered as the dependent variable. Gender and the baseline NPI severity composite score 
were entered as covariates in the model. 
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RESULTS 
Descriptive Statistics 
 Tables 4 and 5 display mean scores on raw cognitive tests at baseline, month 12, 
and month 24 for the overall sample of 1045 participants, as well as mean cognitive 
scores for the AD sample and the non-demented sample. As expected, participants with 
AD had worse cognitive performance than non-demented participants. In addition, 
participants with AD showed a deterioration of their cognitive scores over the two-year 
period, whereas non-demented participants’ cognitive scores remained relatively stable.  
 Neuropsychiatric scores also increased over the two-year period for the entire 
sample, including greater frequency of each individual neuropsychiatric symptom (see 
Table 6). Individuals with AD had higher mean neuropsychiatric scores than the non-
demented participants at each time point (see Table 7). Correspondingly, these demented 
participants also endorsed each neuropsychiatric symptom at a higher frequency than the 
non-demented participants (see Table 8 and Figure 1). Between 73-82% of the AD 
sample reported at least one neuropsychiatric symptom across the two-year time period, 
in contrast to 41-47% of the non-demented sample. The top five endorsed symptoms for 
the AD sample were irritability/lability (32-37%), depression/dysphoria (31-35%), 
anxiety (28-37%), apathy/indifference (24-37%), and agitation/aggression (24-31%). For 
the non-demented sample, the most frequent symptoms were almost identical but rates of 
these symptoms were lower. The top five endorsed symptoms for the non-demented 
sample were irritability/lability (17-20%), depression/dysphoria (15-19%), sleep 
problems (14-17%), agitation/aggression (9-13%), and anxiety (9-11%).   
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Table 4. Raw cognitive scores at baseline, month 12, and month 24. 
Note. N = 1054. Tests are grouped by cognitive domain. RAVLT = Rey Auditory Verbal 
Learning Test. ADAS-cog = Alzheimer’s Disease Assessment Scale-cognitive. Clock = 




Baseline Month 12 Month 24 
Memory    
RAVLT Learning  4.57 (2.65) 4.44 (2.80) 4.31 (2.86) 
RAVLT Short-Delay Recall 5.98 (4.08) 6.00 (4.33) 5.91 (4.57) 
RAVLT Delayed Recall 4.86 (4.28) 4.80 (4.64) 4.66 (4.75) 
RAVLT Recognition 11.14 (3.52) 10.87 (3.92) 10.65 (4.16) 
ADAS-Cog Delayed Recall 4.81 (2.77) 4.84 (3.05) 5.01 (3.17) 
ADAS-Cog Recognition 3.54 (2.71) 3.56 (3.09) 3.99 (3.23) 
Language    
Animals 18.28 (5.48) 18.10 (5.89) 17.42 (6.37) 
Boston Naming Test 26.40 (3.86) 26.62 (4.43) 26.24 (5.03) 
ADAS-Cog Naming .17 (.44) .16 (.45) .21 (.55) 
Visuospatial    
Clock command 4.42 (.87) 4.43 (.90) 4.35 (.99) 
Clock copy 4.75 (.57) 4.77 (.52) 4.68 (.69) 
ADAS-Cog Construction .44 (.54) .46 (.57) .48 (.59) 
Executive/Processing Speed    
Trail Making A 38.79 (16.60) 39.14 (18.42) 40.70 (23.66) 
Trail Making B 106.32 (61.74) 110.55 (71.03) 116.48 (78.22) 
ADAS-Cog Number 
Cancellation 
.65 (.85) .63 (.93) .89 (1.08) 
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Note. AD n = 249. Non-demented n = 796. Tests are grouped by cognitive domain. RAVLT = Rey 
Auditory Verbal Learning Test. ADAS-Cog = Alzheimer’s Disease Assessment Scale-cognitive. Clock = 




Baseline Month 12 Month 24 
Memory    
RAVLT Learning  2.71 (2.01) 2.16 (1.78) 1.88 (1.55) 
RAVLT Short-Delay Recall 2.37 (2.09) 1.98 (1.93) 1.38 (1.75) 
RAVLT Delayed Recall 1.22 (1.90) .70 (1.52) .32 (.94) 
RAVLT Recognition 8.24 (3.89) 7.38 (4.07) 6.56 (4.36) 
ADAS-Cog Delayed Recall 7.59 (2.08) 8.10 (1.90) 8.63 (1.77) 
ADAS-Cog Recognition 5.58 (2.77) 6.27 (3.25) 7.10 (3.04) 
Language    
Animals 15.07 (4.52) 13.75 (5.18) 11.88 (5.12) 
Boston Naming Test 24.15 (5.04) 23.41 (6.01) 21.94 (6.88) 
ADAS-Cog Naming .35 (.61) .39 (.69) .54 (.83) 
Visuospatial    
Clock command 3.86 (1.12) 3.76 (1.20) 3.49 (1.32) 
Clock copy 4.57 (.74) 4.55 (.72) 4.31 (1.03) 
ADAS-Cog Construction .58 (.56) .68 (.67) .80 (.69) 
Executive/Processing Speed    
Trail Making A 48.76 (21.92) 51.51 (24.82) 58.94 (33.13) 
Trail Making B 156.18 (80.19) 175.81 (89.29) 195.76 (96.69) 




Baseline Month 12 Month 24 
Memory    
RAVLT Learning  5.15 (2.56) 5.15 (2.67) 5.07 (2.75) 
RAVLT Short-Delay Recall 7.11 (3.89) 7.26 (4.10) 7.32 (4.25) 
RAVLT Delayed Recall 6.01 (4.18) 6.08 (4.54) 6.02 (4.65) 
RAVLT Recognition 12.04 (2.85) 11.96 (3.15) 11.93 (3.15) 
ADAS-Cog Delayed Recall 3.94 (2.36) 3.81 (2.58) 3.88 (2.63) 
ADAS-Cog Recognition 2.90 (2.36) 2.72 (2.51) 3.01 (2.62) 
Language    
Animals 19.28 (5.37) 19.46 (5.43) 19.16 (5.69) 
Boston Naming Test 27.10 (3.10) 27.62 (3.21) 27.58 (3.30) 
ADAS-Cog Naming .12 (.35) .08 (.32) .11 (.37) 
Visuospatial    
Clock command 4.60 (.70) 4.63 (.66) 4.61 (.67) 
Clock copy 4.81 (.50) 4.84 (.42) 4.79 (.49) 
ADAS-Cog Construction .40 (.52) .39 (.52) .38 (.52) 
Executive/Processing Speed    
Trail Making A 35.67 (13.08) 35.27 (13.80) 35.00 (16.00) 
Trail Making B 90.72 (44.48) 90.13 (48.86) 91.68 (50.34) 
ADAS-Cog Number Cancellation .51 (.73) .43 (.72) .61 (.84) 
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Table 6. Neuropsychiatric scores at baseline, month 12, and month 24. 
 
Note. N = 1054. The NPI Severity Composite represents average severity ratings across NPI and 





Baseline Month 12 Month 24 
N M(SD) N M(SD) N M(SD) 
NPI Severity Composite 1045 1.48 (2.49) 1043 1.92 (2.81) 1042 2.08 (3.13) 
NPI Total  410 2.92 (5.61) 506 4.04 (7.06) 506 4.57 (8.04) 
NPI-Q Total 635 1.57 (2.62) 543 2.11 (3.01) 536 2.28 (3.35) 
    
Symptom Endorsement Y (%) Y (%) Y (%) 
Delusions 11 (1%) 26 (2%) 31 (3%) 
Hallucinations 6 (1%) 11 (1%) 19 (2%) 
Agitation/Aggression 134 (13%) 164 (16%) 178 (17%) 
Depression/Dysphoria 197 (19%) 226 (22%) 225 (22%) 
Anxiety 141 (13%) 170 (16%) 173 (17%) 
Elation/Euphoria 18 (2%) 21 (2%) 27 (3%) 
Apathy/Indifference 120 (11%) 160 (15%) 173 (17%) 
Disinhibition 74 (7%) 92 (9%) 103 (10%) 
Irritability/Lability 216 (21%) 250 (24%) 243 (23%) 
Aberrant Motor Behavior 38 (4%) 52 (5%) 72 (7%) 
Sleep 154 (15%) 194 (19%) 195 (19%) 
Appetite and Eating 
Disorders 
76 (7%) 107 (10%) 134 (13%) 
Any Symptom 509 (49%) 578 (55%) 576 (55%) 
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Table 7. Participants with AD have higher levels of neuropsychiatric symptoms than 




















Baseline         
NPI Severity 
Composite 
796 1.11 (2.01) 249 2.68 (3.34)  -7.04 (306.21) <.001 -.57 
NPI Total 341 2.40 (4.93) 69 5.52 (7.72)  -3.23 (79.59) <.01 -.48 
NPI-Q Total 455 1.11 (2.01) 180 2.72 (3.50)  -5.82 (227.41) <.001 -.56 
Month 12         
NPI Severity 
Composite 
794 1.42 (2.34) 249 3.53 (3.50)  -8.89 (320.09) <.001 -.71 
NPI Total 432 3.24 (6.44) 74 8.68 (8.64)  -5.17 (87.41) <.001 -.71 
NPI-Q Total 368 1.44 (2.32) 175 3.53 (3.73)  -6.81 (239.70) <.001 -.67 
Month 24         
NPI Severity 
Composite 
793 1.40 (2.32) 249 4.23 (4.21)  -10.12 (296.75) <.001 -.83 
NPI Total 432 3.37 (6.36) 74 11.57 (12.24)  -5.63 (79.87) <.001 -.84 
NPI-Q Total 361 1.38 (2.34) 175 4.15 (4.25)  -8.06 (226.59) <.001 -.81 
Note. The NPI Severity Composite represents average severity ratings across NPI and NPI-Q. 
NPI = Neuropsychiatric Index. NPI-Q = Neuropsychiatric Index Questionnaire. Diagnostic 
status of AD or non-demented is based on month 24 diagnosis. 
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Note. AD n = 249. Non-demented n = 796. These ratings represent frequency of endorsement of 
each symptom across the Neuropsychiatric Index and Neuropsychiatric Index Questionnaire. 
AD 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 10 (4%) 21 (8%) 24 (10%) 
Hallucinations 5 (2%) 9 (4%) 15 (6%) 
Agitation/Aggression 60 (24%) 69 (28%) 77 (31%) 
Depression/Dysphoria 76 (31%) 79 (32%) 86 (35%) 
Anxiety 70 (28%) 81 (33%) 91 (37%) 
Elation/Euphoria 8 (3%) 7 (3%) 14 (6%) 
Apathy/Indifference 60 (24%) 88 (35%) 92 (37%) 
Disinhibition 32 (13%) 47 (19%) 55 (22%) 
Irritability/Lability 79 (32%) 90 (36%) 91 (37%) 
Aberrant Motor Behavior 20 (8%) 31 (12%) 51 (20%) 
Sleep 40 (16%) 60 (24%) 69 (28%) 
Appetite and Eating Disorders 40 (16%) 49 (20%) 63 (25%) 
Any Symptom 181 (73%) 205 (82%) 204 (82%) 
NON-DEMENTED 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 1 (0%) 5 (1%) 7 (1%) 
Hallucinations 1 (0%) 2 (0%) 4 (1%) 
Agitation/Aggression 74 (9%) 95 (12%) 101 (13%) 
Depression/Dysphoria 121 (15%) 147 (19%) 139 (18%) 
Anxiety 71 (9%) 89 (11%) 82 (10%) 
Elation/Euphoria 10 (1%) 14 (2%)  13 (2%) 
Apathy/Indifference 60 (8%) 72 (9%) 81 (10%) 
Disinhibition 42 (5%) 45 (6%) 48 (6%) 
Irritability/Lability 137 (17%) 160 (20%) 152 (19%) 
Aberrant Motor Behavior 18 (2%) 21 (3%) 21 (3%) 
Sleep 114 (14%) 134 (17%) 126 (16%) 
Appetite and Eating Disorders 36 (5%) 58 (7%) 71 (9%) 
Any Symptom 328 (41%) 373 (47%) 372 (47%) 
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Note. AD n = 249, Non-demented n = 796. These ratings represent frequency of 
endorsement of each symptom across the Neuropsychiatric Index and Neuropsychiatric 
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Aim 1, Goal A: Develop a cross-sectional model of AD-associated cognitive 
dysfunction. 
A CFA was conducted to test a second-order factor structure of the 
neuropsychological measures. The 15 neuropsychological indicators were hypothesized 
to reflect four latent cognitive domains (memory, language, visuospatial, and 
executive/processing speed). These four latent factors in turn were hypothesized to 
reflect a single higher-order latent factor of AD-associated cognitive dysfunction (see 
Figure 2).  
Using Weighted Least Squares Means and Variance Adjusted estimation, this 
second-order CFA had excellent fit: RMSEA = 0.04, CFI = 0.99, TLI = 0.99. These 
results support a single latent dimension (i.e., AD-associated cognitive dysfunction) 
common to the ADNI neuropsychological measures. Although the 15 
neuropsychological measures indicate four distinct cognitive domains, these four 
domains covary strongly enough with one another that they represent a higher-order 
dimension of cognitive dysfunction. All 15 neuropsychological tests loaded moderately 
to extremely strongly onto their respective cognitive domains, and each of the cognitive 
domains loaded strongly onto the higher-order factor of AD-associated cognitive 
dysfunction (see Figure 2). 
IRT analyses were then conducted to determine how these four 
neuropsychological factors function across the spectrum of AD-associated cognitive 
dysfunction. As illustrated in Table 9 and Figure 3, all four cognitive factors were  
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Figure 2. Higher-order structural model of ADNI neuropsychological tests. 
 
Note. RMSEA = 0.04, CFI = 0.99, TLI = 0.99. Visuosp = Visuospatial. Exec/Proc Speed = 
Executive/Processing Speed. RAVLT = Rey Auditory Verbal Learning Test. RAVLT Learning = number of 
words learned between trial 1 and trial 5 on the RAVLT. RAVLT T6 is a measure of short-delay free recall 
of words on trial 6. DR = Delayed Recall. Recog = Recognition. BNT = Boston Naming Test, and 
represents the numbers of words spontaneously and correctly produced. ADAS-Cog = Alzheimer’s 
Disease Assessment Scale-Cognitive. Clock = Clock Drawing Test; both the command and copy 
conditions are represented. ADAS-Cog Construc = ADAS-Cog Construction subtest. ADAS-Cog Cancel = 
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Table 9. Item parameter estimates for cognitive domains and tests. 
Note. RAVLT = Rey Auditory Verbal Learning Test. ADAS-cog = Alzheimer’s Disease 
Assessment Scale-cognitive. Animals = Category Fluency-Animals. Clock = Clock 
Drawing Test. 
 
Cognitive Indicator a b1 b2 b3 b4 
Memory Composite 1.79 -1.90 -0.69 0.18 1.36 
RAVLT Learning (Trial 5-Trial 1) 2.62 -4.04 -2.23 -0.91 0.19 
RAVLT Short-Delay Recall (Trial 6) 6.30 -1.53 -0.87 -0.30 0.35 
RAVLT 30-Minute Delayed Recall  6.50 -1.69 -1.02 -0.53 -0.01 
RAVLT Recognition 2.93 -0.29 0.50 1.20 1.80 
ADAS-Cog Delayed Recall 4.55 -0.86 -0.22 0.39 0.97 
ADAS-Cog Recognition 2.39 -0.41 0.42 1.36 1.93 
Language Composite 2.04 0.10 1.88 3.27 3.82 
Animals 7.95 -2.32 -1.03 0.11 1.64 
Boston Naming Test 6.08 0.56 1.49 2.10 2.69 
ADAS-Cog Naming 2.75 2.41 3.13 3.44 3.74 
Visuospatial Composite 1.66 1.05 2.27 3.74 4.44 
Clock command 4.92 0.15 1.01 1.57 2.15 
Clock copy 2.52 0.89 1.98 2.76 3.33 
ADAS-Cog Construction 1.15 0.05 3.44 5.64 -- 
Executive/Processing Speed Composite 2.30 0.37 1.14 2.20 2.92 
Trail Making A 3.12 -0.61 1.27 2.00 2.47 
Trail Making B 6.18 -1.06 0.40 0.90 1.18 
ADAS-Cog Number Cancellation 3.34 0.91 1.69 2.27 2.82 
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Figure 3. Differential relationships between four cognitive domains and latent AD-
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moderately to strongly related (Baker, 2001) to the higher-order latent factor (a 
parameters ranged from 1.66 to 2.30). The four cognitive factors differed in their relative 
impairment across the range of AD-associated cognitive dysfunction, as reflected by the 
range of b parameters. The latent dimension of AD-associated cognitive dysfunction was 
represented by a mean of 0 and a standard deviation of 1; lower scores represented 
milder degrees of cognitive dysfunction, whereas higher scores represented more severe 
levels of AD-associated cognitive dysfunction. At the mildest end of the spectrum, 
corresponding to no overt cognitive impairment, the four cognitive domains were all 
relatively intact. However, the curves began to separate between -3 to -0.5 standard 
deviations, suggesting that these distinct cognitive functions optimally discriminated and 
became impaired at different degrees of AD-associated cognitive dysfunction. 
Difficulties with memory were first evident around -3 standard deviations, and 
difficulties with language initially were evident around -2 standard deviations. By 
around -1 standard deviation, the memory and language curves were relatively similar, 
suggesting that language dysfunction “caught up” to memory dysfunction, as assessed 
by the ADNI cognitive measures. Both executive/processing speed and visuospatial 
functions were intact until approximately -0.5 standard deviation, after which the 
executive/processing speed curve had a steeper slope (similar to the slopes of the 
memory and language curves) relative to the visuospatial curve. This finding indicates 
that the visuospatial tests were less discriminating between degrees of AD-associated 
cognitive dysfunction than the memory, language, and executive/processing speed tests. 
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We also examined how the 15 individual neuropsychological measures 
functioned across the spectrum of AD-associated cognitive dysfunction. To do so, we 
used the item parameters for the four cognitive factors (memory, language, visuospatial, 
and executive/processing speed) as “anchors” to define the latent continuum of AD-
associated cognitive dysfunction. Using IRT software (IRT-LR-DIF), we then 
determined the extent to which the 15 cognitive tests indicate that latent continuum. We 
used the initial parameter estimates that were calculated.  
As illustrated in Table 9 and Figures 4 to 7, the cognitive tests were generally 
moderately to strongly related to the latent continuum of AD-associated cognitive 
dysfunction (a parameters ranged from 1.15 to 7.95). Among the memory items, 
indicators of free recall had a stronger relationship to the latent continuum than 
indicators of learning or recognition: RAVLT Short-Delay Recall (a = 6.30), RAVLT 
Delayed Recall (a = 6.50), and ADAS-Cog Delayed Recall (a = 4.55). Among the 
language items, both Animals (a = 7.95) and Boston Naming Test (a = 6.08) were very 
strongly related to the latent continuum. Among the executive/processing speed items, 
Trail Making B (a = 6.18), which involves divided attention, was more strongly related 
to the latent continuum than the other two items (i.e., Trail Making A and ADAS-Cog 
Number Cancellation), which involve more basic visual attention and graphomotor 
speed. ADAS-Cog Construction, a simple visuospatial measure, had the weakest 
relationship to the latent continuum (a = 1.15).  
All 15 cognitive tests also differed in their ability to discriminate between 
degrees of AD-associated cognitive dysfunction (see Table 9 and Figures 4 to 7). Among  
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Note. RAVLT = Rey Auditory Verbal Learning Test. DR = Delayed Recall. ADAS-Cog = 
Alzheimer’s Disease Assessment Scale-cognitive. Recog = Recognition. RAVLT 
Learning is number of words recalled on trial 5 minus number of words recalled on trial 
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Note. Animals = Category Fluency-Animals subtest. Boston Naming Test = number of 
spontaneously correct words. ADAS-Cog Naming = Alzheimer’s Disease Assessment 
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Note. Clock command = Clock Drawing Test command condition. Clock copy = Clock 
Drawing Test copy condition. ADAS-Cog Construction = Alzheimer’s Disease 
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Figure 7. Relationships between executive/processing speed measures and latent AD-
associated cognitive dysfunction. 
 
 
Note. Trail Making A and B are from the Trail Making Test, parts A and B. ADAS-Cog 
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the memory measures, RAVLT Learning was most sensitive to mild degrees of cognitive 
dysfunction, whereas the other tests could better discriminate between moderate degrees 
of cognitive dysfunction. Among the language measures, Animals was sensitive to mild- 
to-moderate degrees of cognitive dysfunction, whereas ADAS-Cog Naming was intact 
until moderate-to-severe levels of cognitive dysfunction. The visuospatial measures as a 
whole remained intact until moderate degrees of cognitive impairment, after which both 
Clock Drawing Test conditions showed good discriminative ability; in contrast, ADAS-
Cog Construction had poor ability to discriminate between degrees of cognitive 
dysfunction. Finally, all three of the executive/processing speed measures could best 
discriminate between moderate degrees of cognitive dysfunction, but Trail Making B 
was optimally sensitive to measuring cognitive impairment approximately one standard 
deviation earlier (milder) than ADAS-Cog Number Cancellation. 
Lastly, we calculated baseline cognitive theta values for each participant using 
item parameters for the four cognitive factors and 15 cognitive tests. This yielded scores 
for each participant on the latent continuum of AD-associated cognitive dysfunction, as 
well as the four latent cognitive domains (i.e., memory, language, visuospatial, and 
executive/processing speed). Cognitive theta values were significantly different between 
the three diagnostic groups (i.e., cognitively intact, MCI, and AD) for all five factors, 
Fs(2, 1042) > 54.92, ps < .001 (see Table 10). Tukey post-hoc analyses indicated that all 
three diagnostic groups were significantly different from one another for all cognitive 
theta values, ps < .05. This confirms the expected pattern: latent cognitive dysfunction  
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Table 10. Latent cognitive scores are significantly different between diagnostic groups at 
baseline. 
 




N = 339 
MCI  
N = 610 
AD  





Global -.59 (.53) -.02 (.66) .81 (.60)  216.92 <.001 
Memory -.72 (.59) .00 (.74) .89 (.52)  249.69 <.001 
Language -.52 (.74) -.09 (.72) .49 (.77)  81.92 <.001 
Visuospatial -.20 (.53) .09 (.66) .54 (.75)  54.92 <.001 
Exec/Proc Speed -.45 (.64) -.09 (.73) .67 (.68)  100.46 <.001 
Note. CN = cognitively normal. SMC = subjective memory concern. MCI = mild 
cognitive impairment. AD = Alzheimer’s disease. Exec/Proc Speed = 
Executive/Processing Speed. Cognitive scores are latent theta scores derived from item 
response theory analyses for each cognitive domain. 
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was mildest for cognitively normal participants, worse for participants with MCI, and 
most severe for participants with AD.  
Aim 1, Goal B: Model longitudinal change in AD-associated cognitive dysfunction. 
We used baseline item parameters for the four cognitive domains and 15 
cognitive tests to estimate theta values for cognitive scores at month 12 and month 24. 
Consistent with the pattern in raw cognitive scores (see Table 4), latent cognitive scores 
(i.e., theta values) were relatively stable for the non-demented group but became worse 
for the participants with AD between baseline to month 24 (see Table 11).  
Repeated-measures ANOVAs revealed a significant linear trend over time for 
global cognitive theta for the entire sample, F(1, 1039) = 4.07, p < .05 (see Table 12). 
There was not a significant linear or quadratic trend over time for the other latent 
cognitive scores for the whole sample. However, all five cognitive domains had a 
significant within-subjects interaction between time and diagnostic status (see Tables 12-
16): global (F[1, 1039] = 197.52, p < .001), memory (F[1, 1039] = 117.33, p < .001), 
language (F[1, 1039] = 82.02, p < .001), visuospatial (F[1, 1039] = 30.04, p < .001), and 
executive/processing speed (F[1, 1039] = 64.37, p < .001). These interactions were 
significant for a linear trend, but not a quadratic trend. The AD participants showed 
steady, linear cognitive decline over the two-year period, whereas the non-demented 
participants had a relatively flat slope, indicating stable cognitive performance (see 
Figures 8-12). 
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Note. The AD group includes participants who were either enrolled with a diagnosis of AD or converted to AD by month 24. 
The non-demented group includes participants with diagnoses of either cognitively normal or mild cognitive impairment at 
month 24. Cognitive scores are latent theta scores derived from item response theory analyses for each cognitive domain. 
Participant 
Subgroup Visit 
 M (SD) 




-.13 (.73) -.15 (.82) -.18 (.79) .04 (.66) -.14 (.76) 
Month 12 -.11 (.83) -.12 (.92) -.16 (.83) .03 (.68) -.13 (.83) 




.59 (.59) .68 (.54) .30 (.73) .46 (.74) .43 (.72) 
Month 12 .80 (.66) .86 (.56) .48 (.75) .53 (.79) .57 (.82) 




-.35 (.62) -.41 (.71) -.33 (.74) -.10 (.58) -.32 (.68) 
Month 12 -.40 (.66) -.42 (.78) -.36 (.75) -.13 (.56) -.36 (.71) 
Month 24 -.35 (.68) -.42 (.81) -.33 (.78) -.10 (.56) -.34 (.76) 
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Table 12. Global cognitive dysfunction: repeated-measures ANOVA within-subjects 
contrasts. 
 
Source Time F(1, 1039) p 
time Linear 4.07 .04 Quadratic 1.46 .23 
time*age Linear .76 .38 Quadratic 1.65 .20 
time*education Linear .03 .88 Quadratic .88 .35 
time*gender Linear .73 .39 Quadratic .54 .46 
time*dx Linear 197.52 <.001 Quadratic .10 .75 
time*gender*dx Linear .25 .62 Quadratic .67 .41 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
Results significant at p < .05 are bolded. 
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Table 13. Memory dysfunction: repeated-measures ANOVA within-subjects contrasts. 
 
Source Time F(1, 1039) p 
time Linear 2.37 .12 Quadratic .04 .85 
time*age Linear .01 .91 Quadratic .01 .93 
time*education Linear 1.80 .18 Quadratic .36 .55 
time*gender Linear .59 .44 Quadratic 3.54 .06 
time*dx Linear 117.33 <.001 Quadratic .28 .60 
time*gender*dx Linear .01 .91 Quadratic 5.86 .02 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
Results significant at p < .05 are bolded. 
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Table 14. Language dysfunction: repeated-measures ANOVA within-subjects contrasts. 
 
Source Time F(1, 1039) p 
time Linear 2.14 .14 Quadratic 1.05 .31 
time*age Linear .21 .65 Quadratic .77 .38 
time*education Linear .25 .62 Quadratic .06 .81 
time*gender Linear .00 .97 Quadratic .05 .83 
time*dx Linear 82.02 <.001 Quadratic .09 .76 
time*gender*dx Linear .09 .77 Quadratic .00 .96 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
Results significant at p < .05 are bolded. 
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Table 15. Visuospatial dysfunction: repeated-measures ANOVA within-subjects 
contrasts. 
 
Source Time F(1, 1039) p 
time Linear .95 .33 Quadratic .06 .81 
time*age Linear .58 .45 Quadratic .05 .83 
time*education Linear .15 .70 Quadratic .19 .67 
time*gender Linear .67 .42 Quadratic .38 .54 
time*dx Linear 30.04 <.001 Quadratic .84 .36 
time*gender*dx Linear .16 .69 Quadratic .02 .88 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
Results significant at p < .05 are bolded. 
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Table 16. Executive/processing speed dysfunction: repeated-measures ANOVA within-
subjects contrasts. 
 
Source Time F(1, 1039) p 
time Linear .03 .86 Quadratic 1.45 .23 
time*age Linear .79 .38 Quadratic 1.77 .18 
time*education Linear .05 .82 Quadratic .37 .54 
time*gender Linear .01 .91 Quadratic .02 .89 
time*dx Linear 64.37 <.001 Quadratic .34 .56 
time*gender*dx Linear .03 .87 Quadratic 1.11 .29 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
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Figure 8. Changes in global cognitive dysfunction depend on diagnostic status. 
 
Note. AD n = 249, Non-demented n = 796. Covariates were entered in the model at the 
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Figure 9. Changes in memory dysfunction depend on diagnostic status. 
 
Note. AD n = 249, Non-demented n = 796. Covariates were entered in the model at the 
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Figure 10. Changes in language dysfunction depend on diagnostic status. 
 
Note. AD n = 249, Non-demented n = 796. Covariates were entered in the model at the 
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Figure 11. Changes in visuospatial dysfunction depend on diagnostic status. 
 
Note. AD n = 249, Non-demented n = 796. Covariates were entered in the model at the 
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Note. AD n = 249, Non-demented n = 755. Covariates were entered in the model at the 
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Aim 2, Goal A: Analyze cross-sectional gender differences in AD-associated 
cognitive dysfunction. 
A series of t-tests revealed significant gender differences at baseline for latent 
global, t(916.68) = 3.19, p < .01, and memory scores, t(891.07) = 4.63, p < .01 (see 
Table 17). There was a trend for a significant gender difference at baseline for latent 
visuospatial scores, t(1005.19) = 1.71, p = .09. Effect sizes were fairly small for these 
gender differences (Cohen’s ds = .11-.29). Men had higher scores than women in all 
three domains, indicating slightly worse cognitive functioning at baseline.  
When the sample was split by diagnostic status (AD versus non-demented at 
month 24), these gender differences at baseline only remained significant for the non-
demented group for latent global, t(794) = 4.30, p < .01, and memory scores, t(794) = 
6.27, p < .01 (see Table 18). Among individuals with AD, women had slightly worse 
cognitive scores than men for global, memory, language, and executive domains. Effect 
sizes for these gender differences were small (Cohen’s ds ranged from .11 to .21) and 
not statistically significant at baseline. 
We next used IRT DIF analyses to examine whether the cross-sectional model of 
AD-associated cognitive dysfunction was invariant across gender. First, we conducted 
DIF analyses on the four cognitive domains (memory, language, visuospatial, 
executive/processing speed), with men serving as the reference group. Results indicated 
that none of these four cognitive factors were invariant across gender. This approach was 
akin to an “omnibus” test for DIF, so it was necessary to next examine for invariance 
across gender for the 15 cognitive tests.  
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Table 17. Gender differences in latent cognitive scores at baseline, month 12, and month 
24. 
 
Note: Female N = 455, Male N = 590. Cognitive scores are latent theta scores derived from 























Baseline -.21 (.78) -.06 (.69)  3.19 (916.68) <.01 -.20 
Month 12 -.18 (.89) -.06 (.78)  2.22 (904.86) <.05 -.14 
Month 24 -.07 (.99) .05 (.89)  2.01 (920.25) <.05 -.13 
Memory 
Baseline -.29 (.88) -.05 (.75)  4.63 (891.07) <.001 -.29 
Month 12 -.23 (1.01) -.03 (.83)  3.52 (863.26) <.001 -.22 
Month 24 -.19 (1.06) .02 (.91)  3.39 (890.40) <.01 -.21 
Language 
Baseline -.16 (.78) -.19 (.79)  -.62 (1043) .53 .04 
Month 12 -.15 (.85) -.16 (.82)  -.24 (1043) .81 .01 
Month 24 -.07 (.97) -.09 (.90)  -.35 (1043) .73 .02 
Visuospatial 
Baseline -.00 (.64) .07 (.68)  1.71 (1005.19) .09 -.11 
Month 12 .01 (.68) .05 (.68)  .89 (1043) .37 -.06 
Month 24 .08 (.75) .12 (.74)  .99 (1043) .32 -.05 
Exec/Proc 
Speed 
Baseline -.16 (.77) -.12 (.75)  .82 (1043) .41 -.05 
Month 12 -.15 (.83) -.12 (.84)  .48 (1043) .63 -.04 
Month 24 -.10 (.94) -.04 (.91)  .96 (1043) .34 -.06 
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Table 18. Gender differences in longitudinal cognitive theta scores vary by clinical 
diagnosis. 
 
Note. AD: Female N = 102, Male N = 147. Non-demented: Female N = 353, Male N = 442. 
Cognitive scores are latent theta scores derived from item response theory analyses for each 











Baseline .64 (.61) .55 (.57)  -1.16 (247) .25 .15 
Month 12 .89 (.66) .74 (.66)  -1.72 (247) .09 .23 
Month 24 1.16 (.75) 1.05 (.78)  -1.05 (247) .30 .14 
Memory 
Baseline .75 (.55) .64 (.54)  -1.58 (247) .12 .20 
Month 12 1.01 (.55) .76 (.54)  -3.45 (247) <.01 .46 
Month 24 1.14 (.48) 1.00 (.59)  -2.12 (240.68) <.05 .26 
Language 
Baseline .35 (.74) .27 (.72)  -.87 (247) .39 .11 
Month 12 .53 (.81) .45 (.71)  -.85 (247) .40 .11 
Month 24 .80 (.90) .69 (.90)  -.91 (247) .36 .12 
Visuospatial 
Baseline .43 (.73) .49 (.74)  .59 (247) .56 -.08 
Month 12 .53 (.80) .53 (.80)  -.04 (247) .97 0 
Month 24 .74 (.93) .74 (.85)  -.07 (247) .95 0 
Exec/Proc 
Speed 
Baseline .52 (.73) .37 (.70)  -1.62 (247) .11 .21 
Month 12 .64 (.81) .53 (.83)  -1.02 (247) .31 .13 











Baseline -.46 (.63) -.27 (.60)  4.30 (.794) <.001 -.31 
Month 12 -.49 (.69) -.33 (.62)  3.37 (714.30) <.01 -.24 
Month 24 -.43 (.73) -.29 (.63)  2.84 (700.30) <.01 -.21 
Memory 
Baseline -.58 (.72) -.27 (.67)  6.27 (794) <.001 -.45 
Month 12 -.59 (.81) -.29 (.73)  5.44 (714.10) <.001 -.39 
Month 24 -.57 (.85) -.30 (.75)  4.70 (704.16) <.001 -.34 
Language 
Baseline -.31 (.73) -.34 (.76)  -.67 (794) .50 .04 
Month 12 -.35 (.76) -.37 (.75)  -.35 (794) .73 .03 
Month 24 -.32 (.84) -.35 (.73)  -.53 (794) .60 .04 
Visuospatial 
Baseline -.13 (.55) -.07 (.60)  1.38 (778.17) .17 -.10 
Month 12 -.14 (.55) -.11 (.56)  .74 (794) .46 -.05 
Month 24 -.12 (.56) -.08 (.57)  .87 (794) .39 -.07 
Exec/Proc 
Speed 
Baseline -.36 (.66) -.28 (.70)  1.49 (794) .14 -.12 
Month 12 -.38 (.68) -.34 (.72)  .71 (794) .48 -.06 
Month 24 -.38 (.77) -.30 (.75)  1.39 (794) .17 -.11 
  80 
There were missing data for several cells when examined within gender (e.g., men had 
missing data for response category “2” on ADAS-Cog Naming, women had missing data 
for response category “4” on ADAS-Cog Construction). Consequently, we recoded the 
data into dichotomous variables, such that response categories of “0” or “1” were 
recoded to a “0” and response categories of “2,” “3,” or “4” were recoded to a “1.” This 
dichotomous recoding represents mild-to-minimal problems (new response category 
“0”) or moderate-to-marked problems (new response category “1”) on any given 
cognitive test.  
Using these newly recoded 15 cognitive indicators, we then proceeded with 
constructing a set of anchor items that were invariant across gender. We iteratively 
removed a single item with the smallest amount of DIF from the larger set of cognitive 
items to add to the set of anchor items. We proceeded with this until the smallest DIF 
value for the remaining candidate items was statistically significant (p < .05). This 
procedure resulted in a set of eight anchor items that were invariant across gender: 
RAVLT Learning, RAVLT Recognition, ADAS-Cog Delayed Recall, ADAS-Cog 
Recognition, ADAS-Cog Naming, ADAS-Cog Number Cancellation, ADAS-Cog 
Construction, and Clock copy. The remaining seven items were candidate items: 
RAVLT Short-Delay Recall, RAVLT Delayed Recall, Animals, Boston Naming Test, 
Clock command, Trail Making A, and Trail Making B. Of these candidate items, Clock 
command had small but significant DIF across gender in both a and b parameters (see 
Figure 13). When not constraining item parameters to be equal in men and women, this 
item was more strongly related to the latent continuum in men (a = 1.42) than women (a  
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Note. Item parameters for women: a = 0.95, b = 2.10. Item parameters for men: a = 
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= 0.95). In addition, the Clock command item discriminated differently between degrees 
of severity along the latent continuum for men than women, based on DIF in the b 
parameter. Clock command discriminated in relatively milder degrees of AD-associated 
cognitive dysfunction for men (b = 1.33) than women (b = 2.10). The remaining six 
candidate items did not show significant DIF in a or b parameters.  
Although the “omnibus” DIF test indicated a violation of invariance for the 
cognitive domains, the only cognitive test that showed significant DIF was the Clock 
command condition. This test was slightly more sensitive to AD-associated cognitive 
dysfunction for men than women. None of the other 14 cognitive tests had significant 
DIF. Therefore, although there were significant gender differences in mean cognitive 
scores, the cognitive tests as a whole seemed to function equivalently as measurements 
of cognitive dysfunction for men and women.  
Aim 2, Goal B: Analyze gender differences in AD-associated cognitive trajectories.  
 The pattern of gender differences in cognitive scores at baseline generally 
remained constant at month 12 and month 24 (see Table 17). For the overall sample, 
there was still a significant gender difference for global theta at month 12, t(904.86) = 
2.22, p < .05, and month 24, t(920.25) = 2.01, p < .05. There was also still a significant 
gender difference for memory theta at month 12, t(863.26) = 3.52, p < .001, and month 
24, t(890.40) = 3.39, p < .01. For global and memory theta scores, men had worse 
cognitive performance than women at month 12 and month 24. 
 There was the same pattern of gender differences in global and memory theta 
scores at month 12 and month 24 for the non-demented sample (see Table 18), with men 
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performing worse than women at each of these two time points. However, among those 
with AD, women had significantly worse memory performance than men at month 12, 
t(247) = 3.45, p < .01, and month 24, t(240.68) = 2.12, p < .05. There was also a trend 
for women to perform worse than men for global theta at month 12, t(247) = 1.72, p = 
.09. These effect sizes ranged from small to medium strength (Cohen’s ds = .23-.46). 
As noted earlier, gender was entered as a between-subjects factor in the repeated-
measures ANOVAs. This allowed us to examine whether women had different rates of 
cognitive change than men between baseline and month 24. There was a significant 
within-subjects interaction between time, gender, and diagnostic status for memory, F(1, 
1039) = 5.86, p < .05 (see Table 13). This interaction was significant for a quadratic 
trend. Among participants with AD, women had a steep rate of decline from baseline to 
month 12, with decelerating but continuing decline from month 12 to month 24 (see 
Figure 14). In contrast, men with AD had a less steep rate of decline from baseline to 
month 12 but had accelerating decline from month 12 to month 24. Among non-
demented participants, both men and women had relatively flat rates of cognitive change 
from baseline to month 24, but men had worse cognitive performance than women (see 
Figure 15).  
There were no significant within-subjects interactions between time and gender 
or between time, gender, and diagnostic status for latent global, language, visuospatial, 
or executive/processing speed scores (see Tables 13, 15-17). However, there was a 
significant between-subjects interaction between gender and diagnostic status for global 
theta averaged across the three time points, F(1, 1039) = 11.06, p < .01. After controlling  
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Figure 14. Women have different rates of memory decline than men in the AD group. 
 
Note. Women n = 102, Men n = 147. Covariates were entered in the model at the 
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Note. Women n = 353, Men n = 443. Covariates were entered in the model at the 
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for age and education, men had worse average global cognitive performance than 
women in the non-demented group, but among the participants with AD, women had 
worse average global cognitive performance than men (see Figures 16 and 17). There 
were also marginally significant between-subjects effects of gender on average memory, 
F(1, 1039) = 3.59, p = .06, and average visuospatial dysfunction, F(1, 1039) = 2.98, p = 
.09. Because the majority of the sample was non-demented, this overall gender effect 
was driven by the non-demented men performing worse than the non-demented women. 
Aim 3, Goal A: Examine whether neuropsychiatric symptoms mediate potential 
gender differences in cross-sectional AD-associated cognitive dysfunction. 
 As reported previously, at baseline in the overall sample, we found significant 
gender differences for mean global and memory theta scores, with a trend for a gender 
difference in mean visuospatial scores. Furthermore, there was a significant gender 
difference for neuropsychiatric symptoms in the overall sample (see Tables 19 and 20). 
Men had significantly higher scores on the NPI severity composite than women at 
baseline, t(1039.88) = 3.36, p < .01, month 12, t(1037.14) = 3.89, p < .001, and month 
24, t(1004.06) = 2.20, p < .05. These gender differences had small effect sizes (Cohen’s 
ds = .14-.24). This pattern of men having higher levels of neuropsychiatric symptoms 
than women was true for the non-demented participants as well as those with AD. In 
addition, men had notably higher rates of specific neuropsychiatric symptoms (see Table 
20 and Figure 18). The neuropsychiatric symptoms with the greatest gender gap in 
endorsement rates included irritability/lability (26-30% of men vs. 14-18% of women),  
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Table 19. Men have higher levels of neuropsychiatric symptoms than women at baseline, 




















Baseline         
NPI Severity 
Composite 
455 1.20 (2.03) 590 1.70 (2.78)  3.36 (1039.88) <.01 -.21 
NPI Total 190 2.36 (5.07) 220 3.41 (6.01)  1.91 (407.80) .06 -.19 
NPI-Q Total 265 1.23 (1.97) 370 1.81 (2.99)  2.94 (629.11) <.01 -.23 
Month 12         
NPI Severity 
Composite 
454 1.55 (2.47) 589 2.21 (3.02)  3.89 (1037.14) <.001 -.24 
NPI Total 232 3.05 (5.12) 274 4.88 (8.27)  3.04 (463.70) <.01 -.27 
NPI-Q Total 224 1.71 (2.89) 319 2.40 (3.07)  2.67 (497.52) <.01 -.23 
Month 24         
NPI Severity 
Composite 
454 1.84 (3.00) 588 2.26 (3.21)  2.20 (1004.06) .03 -.14 
NPI Total 232 4.18 (8.06) 274 4.90 (8.01)  1.01 (504) .31 -.09 
NPI-Q Total 222 2.01 (3.20) 314 2.48 (3.45)  1.62 (496.65) .11 -.14 
 
Note. The NPI Severity Composite represents average severity ratings across NPI and NPI-Q. 
NPI = Neuropsychiatric Index. NPI-Q = Neuropsychiatric Index Questionnaire. 
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Table 20. Neuropsychiatric symptoms differ by gender. 
Note. Women n = 455, men n = 590. These ratings represent frequency of endorsement of each 
symptom across the Neuropsychiatric Index and Neuropsychiatric Index Questionnaire. 
 
WOMEN 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 5 (1%) 12 (3%) 16 (4%) 
Hallucinations 3 (1%) 4 (1%) 12 (3%) 
Agitation/Aggression 43 (9%) 43 (9%) 60 (13%) 
Depression/Dysphoria 89 (20%) 95 (21%) 103 (23%) 
Anxiety 59 (13%) 65 (14%) 72 (16%) 
Elation/Euphoria 3 (1%) 5 (1%) 6 (1%) 
Apathy/Indifference 42 (9%) 54 (12%) 63 (14%) 
Disinhibition 25 (5%) 27 (6%) 32 (7%) 
Irritability/Lability 63 (14%) 71 (16%) 84 (18%) 
Aberrant Motor Behavior 10 (2%) 16 (4%) 25 (5%) 
Sleep 74 (16%) 85 (19%) 82 (18%) 
Appetite and Eating Disorders 27 (6%) 40 (9%) 56 (12%) 
Any Symptom 207 (45%) 231 (51%) 235 (52%) 
MEN 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 6 (1%) 14 (2%) 15 (3%) 
Hallucinations 3 (1%) 7 (1%) 7 (1%) 
Agitation/Aggression 91 (15%) 121 (21%) 118 (20%) 
Depression/Dysphoria 108 (18%) 131 (22%) 122 (21%) 
Anxiety 82 (14%) 105 (18%) 101 (17%) 
Elation/Euphoria 15 (3%) 16 (3%) 21 (4%) 
Apathy/Indifference 78 (13%) 106 (18%) 110 (19%) 
Disinhibition 49 (8%) 65 (11%) 71 (12%) 
Irritability/Lability 153 (26%) 179 (30%) 159 (27%) 
Aberrant Motor Behavior 28 (5%) 36 (6%) 47 (8%) 
Sleep 80 (14%) 109 (18%) 113 (19%) 
Appetite and Eating Disorders 49 (8%) 67 (11%) 78 (13%) 
Any Symptom 302 (51%) 345 (58%) 338 (57%) 
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Note. Women n = 455, men n = 590. These ratings represent frequency of endorsement 
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agitation/aggression (15-20% of men vs. 9-13% of women), apathy/indifference (13-
19% of men vs. 9-14% of women), disinhibition (8-12% of men vs. 5-7% of women), 
and elation/euphoria (3-4% of men vs. 1% of women). Men and women had similar rates 
of the other specific neuropsychiatric symptoms. We conducted a series of regressions to 
test whether neuropsychiatric symptoms mediated any gender effect on cognitive 
dysfunction. There was only evidence of cross-sectional mediation for the 
executive/processing speed domain (see Table 25). After controlling for age and 
education, the effect of gender on executive dysfunction was marginally significant, b = 
-.08, p = .09. After controlling for neuropsychiatric symptoms, the effect of gender on 
executive dysfunction was no longer significant, b = -.04, p = .35.  
 Gender significantly predicted other domains of cognitive dysfunction, but 
neuropsychiatric symptoms did not mediate this effect. After controlling for age and 
education, gender was a significant predictor of global cognitive dysfunction, b = -.20, p 
< .001, memory dysfunction, b = -.28, p < .001, and visuospatial dysfunction, b = -.12, p 
< .01 (see Tables 21-22, 24). However, gender was still a significant predictor after 
controlling for neuropsychiatric symptoms in each of these models: global cognitive 
dysfunction (b = -.16, p < .001), memory dysfunction (b = -.23, p < .001), and 
visuospatial dysfunction (b = -.10, p < .05). Men still had worse performance in each of 
these cognitive areas than women after controlling for age, education, and 
neuropsychiatric symptom severity. Gender did not significantly predict language 
dysfunction after controlling for age and education, b = -.03, p = .61 (see Table 23). 
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 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) for set p  b (s.e.) β  t p 
Step 1: DV = Global Cognitive θ         
1 Age  
.11 
 
65.05 (2, 1042) 
  .02 (.00) .24 8.01 <.001 
 Education <.001  -.06 (.01) -.22 -7.61 <.001 
2 Gender .02 20.21 (1, 1041) <.001  -.20 (.04) -.13 -4.50 <.001 
Step 2: DV = NPI severity score        
1 Age  
.01 
 
5.18 (2, 1042) 
  -.02 (.01) -.05 -1.68 .09 
 Education <.01  -.08 (.03) -.09 -2.85 .01 
2 Gender .02 17.15 (1, 1041) <.001  -.65 (.16) -.13 -4.14 <.001 
Steps 3 & 4: DV = Global Cognitive θ        
1 Age  
.11 
 
65.05 (2, 1042) 
  .02 (.00) .24 8.01 <.001 
 Education <.001  -.06 (.01) -.22 -7.61 <.001 
2 NPI severity score  
.06 
 
38.40 (2, 1040) 
  .06 (.01) .21 7.45 <.001 
 Gender  <.001  -.16 (.04) -.11 -3.63 <.001 
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 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) for set p  b (s.e.) β  t p 
Step 1: DV = Memory θ         
1 Age  
.05 
 
25.07 (2, 1042) 
  .02 (.00) .16 5.19 <.001 
 Education <.001  -.04 (.01) -.14 -4.50 <.001 
2 Gender .03 30.36 (1, 1041) <.001  -.28 (.05) -.17 -5.51 <.001 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.18 (2, 1042) 
  -.02 (.01) -.05 -1.68 .09 
 Education <.01  -.08 (.03) -.09 -2.85 .01 
2 Gender .02 17.15 (1, 1041) <.001  -.65 (.16) -.13 -4.14 <.001 
Steps 3 & 4: DV = Memory θ        
1 Age  
.05 
 
25.07 (2, 1042) 
  .02 (.00) .16 5.19 <.001 
 Education <.001  -.04 (.01) -.14 -4.50 <.001 
2 NPI severity score  
.08 
 
49.34 (2, 1040) 
  .08 (.01) .24 8.15 <.001 
 Gender  <.001  -.23 (.05) -.14 -4.60 <.001 
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 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) for set p  b (s.e.) β  t p 
Step 1: DV = Language θ         
1 Age  
.10 
 
56.33 (2, 1042) 
  .02 (.00) .19 6.42 <.001 
 Education <.001  -.07 (.01) -.24 -8.04 <.001 
2 Gender .00 .26 (1, 1041) .61  -.03 (.05) -.02 -.51 .61 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.18 (2, 1042) 
  -.02 (.01) -.05 -1.68 .09 
 Education <.01  -.08 (.03) -.09 -2.85 .01 
2 Gender .02 17.15 (1, 1041) <.001  -.65 (.16) -.13 -4.14 <.001 
Steps 3 & 4: DV = Language θ        
1 Age  
.10 
 
56.33 (2, 1042) 
  .02 (.00) .19 6.42 <.001 
 Education <.001  -.07 (.01) -.24 -8.04 <.001 
2 NPI severity score  
.02 
 
8.79 (2, 1040) 
  .04 (.01) .12 4.16 <.001 
 Gender  <.001  .00 (.05) .00 .02 .98 
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 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) for set p  b (s.e.) β  t p 
Step 1: DV =  Visuospatial θ         
1 Age  
.06 
 
30.06 (2, 1042) 
  .01 (.00) .13 4.26 <.001 
 Education <.001  -.05 (.01) -.19 -6.20 <.001 
2 Gender .01 7.70 (1, 1041) <.01  -.12 (.04) -.09 -2.78 <.01 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.18 (2, 1042) 
  -.02 (.01) -.05 -1.68 .09 
 Education <.01  -.08 (.03) -.09 -2.85 .01 
2 Gender .02 17.15 (1, 1041) <.001  -.65 (.16) -.13 -4.14 <.001 
Steps 3 & 4: DV =  Visuospatial θ        
1 Age  
.06 
 
30.06 (2, 1042) 
  .01 (.00) .13 4.26 <.001 
 Education <.001  -.05 (.01) -.19 -6.20 <.001 
2 NPI severity score  
.02 
 
10.77 (2, 1040) 
  .03 (.01) .11 3.71 <.001 
 Gender  <.001  -.10 (.04) -.07 -2.30 .02 
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 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) for set p  b (s.e.) β  t p 
Step 1: DV = Executive θ         
1 Age  
.12 
 
67.65 (2, 1042) 
  .03 (.00) .25 8.71 <.001 
 Education <.001  -.06 (.01) -.21 -7.17 <.001 
2 Gender .00 2.82 (1, 1041) .09  -.08 (.05) -.05 -1.68 .09 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.18 (2, 1042) 
  -.02 (.01) -.05 -1.68 .09 
 Education <.01  -.08 (.03) -.09 -2.85 .01 
2 Gender .02 17.15 (1, 1041) <.001  -.65 (.16) -.13 -4.14 <.001 
Steps 3 & 4: DV =  Executive θ        
1 Age  
.12 
 
67.65 (2, 1042) 
  .03 (.00) .25 8.71 <.001 
 Education <.001  -.06 (.01) -.21 -7.17 <.001 
2 NPI severity score  
.03 
 
19.27 (2, 1040) 
  .05 (.01) .17 5.97 <.001 
 Gender  <.001  -.04 (.05) -.03 -.94 .35 
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Diagnostic status moderated the mediation of executive/processing speed. 
Neuropsychiatric symptoms only mediated the effect of gender on executive/processing 
speed for the non-demented participants, but not for individuals with AD (see Table 30). 
Neuropsychiatric symptoms did not mediate the effect of gender for any of the other 
cognitive domains for participants with AD or for non-demented participants (see Tables 
26-29). 
 We also tested whether the baseline NPI severity composite score would mediate 
the effect of gender on cognitive dysfunction at month 24. The same findings emerged: 
neuropsychiatric symptoms mediated the effect of gender on executive/processing speed 
dysfunction, but only for non-demented participants. In this non-demented sample, after 
controlling for age and education, the effect of gender on executive/processing speed 
dysfunction was marginally significant, b = -.10, p = .06 (see Table 35). After entering 
the baseline NPI severity composite score as a predictor into the regression model, the 
effect of gender on executive dysfunction was no longer significant, b = -.08, p = 13. 
There was not evidence that the baseline NPI severity composite mediated any other 
gender effect for any of the other cognitive domains at month 24 (see Tables 31-35). 
Aim 3, Goal B: Examine whether neuropsychiatric symptoms mediate potential 
gender differences in AD-associated cognitive change.  
 Although there was not strong evidence of neuropsychiatric symptoms mediating 
the effect of gender on cognitive dysfunction at baseline or month 24, we wanted to 
examine whether neuropsychiatric symptoms might drive gender differences in cognitive 
change between baseline and month 24. To analyze this, we entered the NPI severity 
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Table 26. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
global cognitive dysfunction. 
 
Note: Baseline NPI severity composite score and baseline global cognitive theta score were entered in the 
above models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Global Cognitive θ        
1 Age  
.06 
 
7.21 (2, 246) 
  .01 (.01) .15 2.44 .02 
 Education <.01  -.04 (.01) -.19 -3.07 <.01 
2 Gender .00 .63 (1, 245) .43  .06 (.08) .05 .79 .43 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Global Cognitive θ        
1 Age  
.06 
 
7.21 (2, 246) 
  .01 (.01) .15 2.44 .02 
 Education <.01  -.04 (.01) -.19 -3.07 <.01 
2 NPI severity score  
.01 
 
.60 (2, 244) 
  .01 (.01) .05 .76 .45 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Global Cognitive θ        
1 Age  
.12 
 
56.00 (2, 793) 
  .02 (.00) .27 8.09 <.001 
 Education <.001  -.05 (.01) -.20 -6.01 <.001 
2 Gender .03 29.69 (1, 792) <.001  -.23 (.04) -.18 -5.45 <.001 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Global Cognitive θ        
1 Age  
.12 
 
56.00 (2, 793) 
  .02 (.00) .27 8.09 <.001 
 Education <.001  -.05 (.01) -.20 -6.01 <.001 
2 NPI severity score  
.05 
 
23.36 (2, 791) 
  .04 (.01) .13 4.06 <.001 
 Gender  <.001  -.21 (.04) -.17 -4.95 <.001 
  100 
Table 27. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
memory dysfunction. 
 
Note: Baseline NPI severity composite score and baseline memory theta score were entered in the above 
models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory and 





 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Memory θ        
1 Age  
.02 
 
2.03 (2, 246) 
  .01 (.01) .10 1.63 .10 
 Education .13  -.02 (.01) -.08 -1.29 .20 
2 Gender .01 2.35 (1, 245) .13  .11 (.07) .10 1.53 .13 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Memory θ        
1 Age  
.02 
 
2.03 (2, 246) 
  .01 (.01) .10 1.63 .10 
 Education .13  -.02 (.01) -.08 -1.29 .20 
2 NPI severity score  
.02 
 
2.95 (2, 244) 
  .02 (.01) .12 1.88 .06 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Memory θ         
1 Age  
.04 
 
16.13 (2, 793) 
  .02 (.00) .16 4.64 <.001 
 Education <.001  -.03 (.01) -.10 -2.81 <.01 
2 Gender .05 47.04 (1, 972) <.001  -.34 (.05) -.24 -6.86 <.001 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Memory θ        
1 Age  
.04 
 
16.13 (2, 793) 
  .02 (.00) .16 4.64 <.001 
 Education <.001  -.03 (.01) -.10 -2.81 <.01 
2 NPI severity score  
.07 
 
32.24 (2, 791) 
  .05 (.01) .14 4.06 <.001 
 Gender  <.001  -.32 (.05) -.22 -6.36 <.001 
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Table 28. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
language dysfunction. 
 
Note: Baseline NPI severity composite score and baseline language theta score were entered in the above 
models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory and 





 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Language θ        
1 Age  
.08 
 
9.93 (2, 246) 
  .02 (.01) .18 2.92 <.01 
 Education <.001  -.06 (.02) -.22 -3.56 <.001 
2 Gender .00 .19 (1, 245) .67  .04 (.09) .03 .43 .67 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Language θ        
1 Age  
.08 
 
9.93 (2, 246) 
  .02 (.01) .18 2.92 <.01 
 Education <.001  -.06 (.02) -.22 -3.56 <.001 
2 NPI severity score  
.00 
 
.24 (2, 244) 
  .01 (.01) .03 .54 .59 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Language θ         
1 Age  
.09 
 
38.12 (2, 793) 
  .02 (.00) .18 5.33 <.001 
 Education <.001  -.06 (.01) -.22 -6.37 <.001 
2 Gender .00 .07 (1, 792) .79  -.01 (.05) -.01 -.26 .79 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Language θ        
1 Age  
.09 
 
38.12 (2, 793) 
  .02 (.00) .18 5.33 <.001 
 Education <.001  -.06 (.01) -.22 -6.37 <.001 
2 NPI severity score  
.00 
 
1.37 (2, 791) 
  .02 (.01) .06 1.63 .10 
 Gender  .26  -.00 (.05) -.00 -.06 .96 
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Table 29. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
visuospatial dysfunction. 
 
Note: Baseline NPI severity composite score and baseline visuospatial theta score were entered in the 
above models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Visuospatial θ        
1 Age  
.02 
 
2.07 (2, 246) 
  .01 (.01) .08 1.33 .19 
 Education .13  -.03 (.02) -.10 -1.63 .11 
2 Gender .00 .70 (1, 245) .40  -.08 (.10) -.06 -.84 .40 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Visuospatial θ        
1 Age  
.02 
 
2.07 (2, 246) 
  .01 (.01) .08 1.33 .19 
 Education .13  -.03 (.02) -.10 -1.63 .11 
2 NPI severity score  
.01 
 
.70 (2, 244) 
  -.01 (.01) -.05 -.83 .41 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Visuospatial θ         
1 Age  
.06 
 
23.61 (2, 793) 
  .01 (.00) .13 3.67 <.001 
 Education <.001  -.04 (.01) -.19 -5.43 <.001 
2 Gender .01 5.55 (1, 792) .02  -.10 (.04) -.08 -2.36 .02 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Visuospatial θ        
1 Age  
.06 
 
23.61 (2, 793) 
  .01 (.00) .13 3.67 <.001 
 Education <.001  -.04 (.01) -.19 -5.43 <.001 
2 NPI severity score  
.01 
 
5.49 (2, 791) 
  .02 (.01) .08 2.32 .02 
 Gender  <.01  -.09 (.04) -.07 -2.05 .04 
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Table 30. Baseline neuropsychiatric symptoms mediate the effect of gender on 
executive/processing speed dysfunction for non-demented older adults. 
 
Note: Baseline NPI severity composite score and baseline executive/processing speed theta score were 
entered in the above models. The NPI severity score is a composite of severity ratings on the 





 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Exec/Proc Speed θ        
1 Age  
.07 
 
9.26 (2, 246) 
  .02 (.01) .16 2.63 .01 
 Education <.001  -.06 (.02) -.22 -3.58 <.001 
2 Gender .01 1.42 (1, 245) .24  .11 (.09) .08 1.19 .24 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Exec/Proc Speed θ        
1 Age  
.07 
 
9.26 (2, 246) 
  .02 (.01) .16 2.63 .01 
 Education <.001  -.06 (.02) -.22 -3.58 <.001 
2 NPI severity score  
.01 
 
.78 (2, 244) 
  .01 (.01) .03 .40 .69 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Exec/Proc Speed θ        
1 Age  
.12 
 
54.56 (2, 793) 
  .03 (.00) .29 8.61 <.001 
 Education <.001  -.04 (.01) -.17 -5.05 <.001 
2 Gender .01 4.23 (1, 792) .04  -.10 (.05) -.07 -2.06 .04 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Exec/Proc Speed θ        
1 Age  
.12 
 
54.56 (2, 793) 
  .03 (.00) .29 8.61 <.001 
 Education <.001  -.04 (.01) -.17 -5.05 <.001 
2 NPI severity score  
.02 
 
8.67 (2, 791) 
  .04 (.01) .12 3.61 <.001 
 Gender  <.001  -.08 (.05) -.06 -1.60 .11 
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Table 31. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
global cognitive dysfunction at month 24. 
 
Note: Baseline NPI severity composite score and month 24 global cognitive theta score were entered in 
the above models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric 





 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Global Cognitive θ        
1 Age  
.02 
 
1.95 (2, 246) 
  .01 (.01) .06 .90 .37 
 Education .14  -.03 (.02) -.12 -.181 .07 
2 Gender .00 .58 (1, 245) .45  .08 (.10) .05 .76 .45 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Global Cognitive θ        
1 Age  
.02 
 
1.95 (2, 246) 
  .01 (.01) .06 .90 .37 
 Education .14  -.03 (.02) -.12 -1.81 .07 
2 NPI severity score  
.02 
 
2.37 (2, 244) 
  .03 (.02) .13 2.04 .04 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Global Cognitive θ        
1 Age  
.11 
 
46.33 (2, 793) 
  .02 (.00) .24 7.05 <.001 
 Education <.001  -.05 (.01) -.20 -5.84 <.001 
2 Gender .02 15.03 (1, 792) <.001  -.18 (.05) -.13 -3.88 <.001 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Global Cognitive θ        
1 Age  
.11 
 
46.33 (2, 793) 
  .02 (.00) .24 7.05 <.001 
 Education <.001  -.05 (.01) -.20 -5.84 <.001 
2 NPI severity score  
.03 
 
13.58 (2, 791) 
  .04 (.01) .12 3.45 <.01 
 Gender  <.001  -.16 (.05) -.12 -3.44 <.01 
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Table 32. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
memory dysfunction at month 24. 
 
Note: Baseline NPI severity composite score and month 24 memory theta score were entered in the above 
models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory and 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Memory θ        
1 Age  
.01 
 
.64 (2, 246) 
  -.00 (.01) -.02 -.33 .75 
 Education .53  -.01 (.01) -.07 -1.06 .29 
2 Gender .01 3.27 (1, 245) .07  .13 (.07) .12 1.81 .07 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Memory θ        
1 Age  
.01 
 
.64 (2, 246) 
  -.00 (.01) -.02 -.33 .75 
 Education .53  -.01 (.01) -.07 -1.06 .29 
2 NPI severity score  
.01 
 
1.73 (2, 244) 
  .01 (.01) .03 .45 .65 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Memory θ        
1 Age  
.05 
 
19.96 (2, 793) 
  .02 (.00) .17 4.86 <.001 
 Education <.001  -.04 (.01) -.12 -3.55 <.001 
2 Gender .03 29.72 (1, 792) <.001  -.31 (.06) -.19 -5.45 <.001 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Memory θ        
1 Age  
.05 
 
19.96 (2, 793) 
  .02 (.00) .17 4.86 <.001 
 Education <.001  -.04 (.01) -.12 -3.55 <.001 
2 NPI severity score  
.05 
 
20.31 (2, 791) 
  .05 (.01) .11 3.25 <.01 
 Gender  <.001  -.29 (.06) -.18 -5.03 <.001 
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Table 33. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
language dysfunction at month 24. 
 
Note: Baseline NPI severity composite score and month 24 language theta score were entered in the above 
models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory and 





 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Language θ        
1 Age  
.05 
 
6.10 (2, 246) 
  .01 (.01) .10 1.54 .13 
 Education <.01  -.06 (.02) -.20 -3.23 <.01 
2 Gender .00 .14 (1, 245) .71  .04 (.12) .02 .37 .71 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Language θ        
1 Age  
.05 
 
6.10 (2, 246) 
  .01 (.01) .10 1.54 .13 
 Education <.01  -.06 (.02) -.20 -3.23 <.01 
2 NPI severity score  
.02 
 
2.29 (2, 244) 
  .04 (.02) .13 2.11 .04 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Language θ        
1 Age  
.08 
 
36.33 (2, 793) 
  .02 (.00) 1.8 5.19 <.001 
 Education <.001  -.06 (.01) -.21 -6.23 <.001 
2 Gender .00 .16 (1, 792) .69  -.02 (.06) -.01 -.40 .69 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Language θ        
1 Age  
.08 
 
36.33 (2, 793) 
  .02 (.00) .19 5.36 <.001 
 Education <.001  -.06 (.01) -.21 -5.92 <.001 
2 NPI severity score  
.01 
 
2.49 (2, 791) 
  .03 (.01) .08 2.19 .03 
 Gender  .08  -.01 (.06) -.00 -.12 .91 
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Table 34. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
visuospatial dysfunction at month 24. 
 
Note: Baseline NPI severity composite score and month 24 visuospatial theta score were entered in the 
above models. The NPI severity score is a composite of severity ratings on the Neuropsychiatric Inventory 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Visuospatial θ        
1 Age  
.01 
 
1.19 (2, 246) 
  -.00 (.01) -.02 -.29 .77 
 Education .31  -.03 (.02) -.10 -1.49 .14 
2 Gender .00 .10 (1, 245) .75  -.04 (.12) -.02 -.32 .75 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV = Visuospatial θ        
1 Age  
.01 
 
1.19 (2, 246) 
  -.00 (.01) -.02 -.29 .77 
 Education .31  -.03 (.02) -.10 -1.49 .14 
2 NPI severity score  
.01 
 
.69 (2, 244) 
  .02 (.02) .07 1.13 .26 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Visuospatial θ        
1 Age  
.05 
 
21.83 (2, 793) 
  .01 (.00) .14 3.88 <.001 
 Education <.001  -.04 (.01) -.17 -4.95 <.001 
2 Gender .00 2.90 (1, 792) .09  -.07 (.04) -.06 -1.70 .09 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV = Visuospatial θ        
1 Age  
.05 
 
21.83 (2, 793) 
  .01 (.00) .14 3.88 <.001 
 Education <.001  -.04 (.01) -.17 -4.95 <.001 
2 NPI severity score  
.01 
 
3.21 (2, 791) 
  .02 (.01) .07 1.88 .06 
 Gender  .04  -.06 (.04) -.05 -1.46 .15 
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Table 35. Baseline neuropsychiatric symptoms do not mediate the effect of gender on 
executive/processing speed dysfunction at month 24. 
 
Note: Baseline NPI severity composite score and month 24 executive/processing speed theta score were 
entered in the above models. The NPI severity score is a composite of severity ratings on the 
Neuropsychiatric Inventory and Neuropsychiatric Inventory-Questionnaire. Exec/Proc Speed = 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV = Exec/Proc Speed θ        
1 Age  
.02 
 
2.33 (2, 246) 
  .01 (.01) .08 1.19 .24 
 Education .10  -.04 (.02) -.12 -1.88 .06 
2 Gender .00 .79 (1, 245) .38  .10 (.12) .06 .89 .38 
Step 2: DV = NPI severity score        
1 Age  
.00 
 
.44 (2, 246) 
  -.01 (.03) -.02 -.23 .82 
 Education .64  -.07 (.08) -.06 -.89 .37 
2 Gender .01 3.48 (1, 245) .06  -.83 (.44) -.12 -1.87 .06 
Steps 3 & 4: DV =  Exec/Proc Speed θ        
1 Age  
.02 
 
2.33 (2, 246) 
  .01 (.01) .08 1.19 .24 
 Education .10  -.04 (.02) -.12 -1.88 .06 
2 NPI severity score  
.01 
 
1.24 (2, 244) 
  .02 (.02) .08 1.30 .19 




 Model  Coefficients 
Predictors in Set ΔR2 ΔF (df) p  b (s.e.) β  t p 
Step 1: DV =  Exec/Proc Speed θ        
1 Age  
.13 
 
60.64 (2, 793) 
  .03 (.00) .31 9.34 <.001 
 Education <.001  -.05 (.01) -.16 -4.91 <.001 
2 Gender .00 3.49 (1, 792) .06  -.10 (.05) -.06 -1.87 .06 
Step 2: DV =  NPI severity score        
1 Age  
.01 
 
5.70 (2, 793) 
  -.03 (.01) -.10 -2.89 <.01 
 Education <.01  -.05 (.03) -.07 -2.02 <.05 
2 Gender .02 12.63 (1, 792) <.001  -.52 (.15) -.13 -3.55 <.001 
Steps 3 & 4: DV =  Exec/Proc Speed θ        
1 Age  
.13 
 
60.64 (2, 793) 
  .03 (.00) .31 9.34 <.001 
 Education <.001  -.05 (.01) -.16 -4.91 <.001 
2 NPI severity score  
.01 
 
5.38 (2, 791) 
  .03 (.01) .09 2.69 <.01 
 Gender  <.01  -.08 (.05) -.05 -1.52 .13 
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composite score as a covariate into the repeated-measures ANOVA models. As 
previously described, without controlling for neuropsychiatric symptoms, we found a 
significant within-subjects interaction between time, gender, and diagnostic status for 
memory. We also found a significant between-subjects interaction between gender and 
diagnostic status for average global cognitive dysfunction, as well as marginally 
significant effects of gender on average memory and average visuospatial dysfunction.  
After entering neuropsychiatric symptoms as a covariate in these repeated-measures 
ANOVA models (see Tables 36-40), there was still a significant within-subjects 
interaction between time, gender, and diagnostic status for a quadratic trend for memory, 
F(1, 1038) = 5.71, p = .02. Controlling for neuropsychiatric symptoms did not change 
the statistical significance of this interaction. The between-subjects interaction between 
gender and diagnostic status for average global cognitive dysfunction was also still 
significant after controlling for neuropsychiatric symptoms, F(1, 1038) = 12.04, p < .01. 
In contrast, after controlling for neuropsychiatric symptoms, the between-subjects effects 
of gender were no longer significant for average memory, F(1, 1038) = 2.26, p = .13, or 
average visuospatial dysfunction, F(1, 1038) = 2.37, p = .12. Interestingly, there was a 
significant within- subjects interaction between time and neuropsychiatric symptoms for 
a linear trend for language, F(1, 1038) = 4.16, p < .05. This suggests that the progression 
of change in language abilities was partially dependent on baseline neuropsychiatric 
symptoms.  
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Table 36. Global cognitive dysfunction: repeated-measures ANOVA within-subjects 
contrasts with neuropsychiatric symptoms as covariate. 
 
Source Time F(1, 1038) p 
time Linear 3.08 .08 Quadratic 1.03 .31 
time*age Linear .57 .45 Quadratic 1.42 .23 
time*education Linear .08 .78 Quadratic .71 .40 
time*NPI Linear 1.86 .17 Quadratic 1.09 .30 
time*gender Linear 1.01 .31 Quadratic .72 .40 
time*dx Linear 175.37 <.001 Quadratic .00 .97 
time*gender*dx Linear .21 .65 Quadratic .72 .40 
 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
NPI represents the NPI severity composite score. The NPI severity score is a composite 
of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric Inventory-
Questionnaire. Results significant at p < .05 are bolded. 
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Table 37. Memory dysfunction: repeated-measures ANOVA within-subjects contrasts 
with neuropsychiatric symptoms as covariate. 
 
Source Time F(1, 1038) p 
time Linear 3.18 .08 Quadratic .15 .70 
time*age Linear .00 .99 Quadratic .00 .99 
time*education Linear 2.17 .14 Quadratic .49 .49 
time*NPI Linear 2.38 .12 Quadratic 1.32 .25 
time*gender Linear .34 .56 Quadratic 3.01 .08 
time*dx Linear 118.23 <.001 Quadratic .65 .42 
time*gender*dx Linear .02 .88 Quadratic 5.71 .02 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
NPI represents the NPI severity composite score. The NPI severity score is a composite 
of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric Inventory-
Questionnaire. Results significant at p < .05 are bolded. 
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Table 38. Language dysfunction: repeated-measures ANOVA within-subjects contrasts 
with neuropsychiatric symptoms as covariate. 
 
Source Time F(1, 1038) p 
time Linear 1.19 .28 Quadratic 1.14 .29 
time*age Linear .08 .77 Quadratic .82 .37 
time*education Linear .10 .75 Quadratic .07 .79 
time*NPI Linear 4.16 .04 Quadratic .12 .73 
time*gender Linear .08 .78 Quadratic .03 .87 
time*dx Linear 68.00 <.001 Quadratic .15 .70 
time*gender*dx Linear .13 .72 Quadratic .00 .95 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
NPI represents the NPI severity composite score. The NPI severity score is a composite 
of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric Inventory-
Questionnaire. Results significant at p < .05 are bolded. 
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Table 39. Visuospatial dysfunction: repeated-measures ANOVA within-subjects 
contrasts with neuropsychiatric symptoms as covariate. 
 
Source Time F(1, 1038) p 
time Linear .56 .46 Quadratic .00 .97 
time*age Linear .43 .51 Quadratic .10 .76 
time*education Linear .24 .62 Quadratic .11 .74 
time*NPI Linear 1.55 .21 Quadratic 1.32 .25 
time*gender Linear .91 .34 Quadratic .23 .63 
time*dx Linear 24.81 <.001 Quadratic .35 .56 
time*gender*dx Linear .19 .66 Quadratic .02 .90 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
NPI represents the NPI severity composite score. The NPI severity score is a composite 
of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric Inventory-
Questionnaire. Results significant at p < .05 are bolded. 
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Table 40. Executive/processing speed dysfunction: repeated-measures ANOVA within-
subjects contrasts with neuropsychiatric symptoms as covariate. 
 
Source Time F(1, 1038) p 
time Linear .06 .81 Quadratic 1.17 .28 
time*age Linear .84 .36 Quadratic 1.63 .20 
time*education Linear .07 .80 Quadratic .31 .58 
time*NPI Linear .15 .70 Quadratic .35 .56 
time*gender Linear .00 .95 Quadratic .01 .94 
time*dx Linear 58.58 <.001 Quadratic .52 .47 
time*gender*dx Linear .02 .88 Quadratic 1.07 .30 
Note: dx is a binary variable representing diagnosis at month 24: AD or non-demented. 
NPI represents the NPI severity composite score. The NPI severity score is a composite 
of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric Inventory-
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Aim 4: Analyze whether gender or neuropsychiatric symptoms predict odds of 
conversion to AD.  
A binary logistic regression was conducted to analyze whether the odds of 
conversion to AD was related to either gender or neuropsychiatric symptoms. In the 
model, a binary variable representing conversion from CN or MCI to AD (0 = no, 1 = 
yes) was entered as the dependent variable. Gender and the baseline NPI severity 
composite score were entered as covariates in the model. The overall model was 
significant, χ2 = 31.97, p < .001. The model accurately predicted status on the 
conversion to AD variable approximately 84% of the time. The coefficient for gender 
was not statistically significant, b = .08, Wald χ2 = .18, p = .68. In contrast, the 
coefficient for the baseline NPI severity composite score was statistically significant, b = 
.18, Wald χ2 = 29.66, p < .001. A one-unit increase in NPI severity composite score 
multiplied the predicted odds of converting to AD by 1.20.  
Consistent with these results, participants who converted to AD by month 24 had 
significantly higher scores on the NPI severity composite at baseline, t(207.56) = 2.62, p 
< .05, month 12, t(231.13) = 4.14, p < .001, and month 24, t(201.27) = 6.05, p < .001, 
compared to participants who did not convert from non-demented aging to AD (see 
Table 41). The effect sizes for these differences were small to medium (Cohen’s ds = 
.27-.62). Converters also had notably higher rates of each specific neuropsychiatric 
symptom compared to non-converters (see Table 42 and Figure 19). Between 67-82% of 
converters reported any neuropsychiatric symptom, in contrast to 56-62% of non-
converters.  
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Baseline         
NPI Severity 
Composite 
153 2.42 (3.41) 424 1.64 (2.37)  2.62 (207.56) .01 .27 
NPI Total 50 4.76 (6.53) 176 3.69 (6.15)  1.07 (224) .28 .17 
NPI-Q Total 103 2.47 (3.81) 248 1.63 (2.35)  2.08 (135.31) .04 .27 
Month 12         
NPI Severity 
Composite 
153 3.14 (3.17) 422 1.96 (2.61)  4.14 (231.13) <.001 .41 
NPI Total 55 8.22 (8.14) 256 4.14 (6.79)  3.47 (71.06) <.01 .54 
NPI-Q Total 98 2.98 (3.34) 167 2.19 (2.71)  2.11 (263) .04 .26 
Month 24         
NPI Severity 
Composite 
153 4.19 (4.09) 422 2.04 (2.68)  6.05 (201.27) <.001 .62 
NPI Total 55 11.91 (12.51) 262 4.62 (7.20)  4.18 (61.71) <.001 .71 
NPI-Q Total 98 3.99 (3.99) 160 2.21 (2.87)  3.84 (158.44) <.001 .51 
Note. MCI = mild cognitive impairment. AD = Alzheimer’s disease. The NPI Severity Composite 
score is an average of severity ratings on the Neuropsychiatric Inventory and Neuropsychiatric 
Inventory-Questionnaire. Converters = participants who convert from MCI to AD between 
baseline and month 24. Non-Converters = participants whose diagnosis remains stable as MCI 
between baseline and month 24 (i.e., they do not convert to AD). 
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Table 42. Neuropsychiatric symptom endorsement differs for MCI participants based on 
conversion status. 
 
Note. MCI = mild cognitive impairment. AD = Alzheimer’s disease. Converters to AD: n = 153; 
non-converters: n = 424 at baseline, n = 422 at month 12 and month 24. Converters = 
participants who convert from MCI to AD between baseline and month 24. Non-Converters = 
participants whose diagnosis remains stable as MCI between baseline and month 24 (i.e., they 
do not convert to AD). These ratings represent frequency of endorsement of each symptom 
across the Neuropsychiatric Index and Neuropsychiatric Index Questionnaire. 
 
CONVERTERS TO AD 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 4 (3%) 7 (5%) 12 (8%) 
Hallucinations 3 (2%) 5 (3%) 9 (6%) 
Agitation/Aggression 35 (23%) 38 (25%) 49 (32%) 
Depression/Dysphoria 43 (28%) 49 (32%) 61 (40%) 
Anxiety 34 (22%) 47 (31%) 47 (31%) 
Elation/Euphoria 4 (3%) 3 (2%) 6 (4%) 
Apathy/Indifference 30 (20%) 51 (33%) 58 (38%) 
Disinhibition 14 (9%) 21 (14%) 30 (20%) 
Irritability/Lability 49 (32%) 55 (36%) 60 (39%) 
Aberrant Motor Behavior 6 (4%) 11 (7%) 27 (18%) 
Sleep 22 (14%) 36 (24%) 44 (29%) 
Appetite and Eating Disorders 25 (16%) 32 (21%) 42 (27%) 
Any Symptom 103 (67%) 121 (79%) 125 (82%) 
NON-CONVERTERS 
Symptom Endorsement: Y (%) Baseline Month 12 Month 24 
Delusions 1 (0%) 3 (1%) 6 (1%) 
Hallucinations 0 (0%) 2 (0%) 4 (1%) 
Agitation/Aggression 64 (15%) 73 (17%) 83 (20%) 
Depression/Dysphoria 89 (21%) 106 (25%) 107 (25%) 
Anxiety 52 (12%) 68 (16%) 71 (17%) 
Elation/Euphoria 10 (2%) 12 (3%) 12 (3%) 
Apathy/Indifference 51 (12%) 55 (13%) 61 (14%) 
Disinhibition 36 (8%) 36 (9%) 37 (9%) 
Irritability/Lability 101 (24%) 118 (28%) 110 (26%) 
Aberrant Motor Behavior 16 (4%) 18 (4%) 18 (4%) 
Sleep 76 (18%) 91 (22%) 85 (20%) 
Appetite and Eating Disorders 30 (7%) 36 (9%) 49 (12%) 
Any Symptom 238 (56%) 261 (62%) 260 (62%) 
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Figure 19. Baseline endorsement of neuropsychiatric symptoms differs for MCI 




Note. MCI = mild cognitive impairment. Converters to Alzheimer’s disease: n = 153; 
non-converters: n = 424 at baseline, n = 422 at month 12 and month 24.  Converters = 
participants who convert from MCI to Alzheimer’s disease between baseline and month 
24. Non-Converters = participants whose diagnosis remains stable as MCI between 
baseline and month 24 (i.e., they do not convert to Alzheimer’s disease). These ratings 
represent frequency of endorsement of each symptom across the Neuropsychiatric Index 
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SUMMARY AND DISCUSSION 
 In light of important, unanswered questions about the relationships among 
gender, neuropsychiatric symptoms, and cognitive dysfunction in AD, the current study 
had four main aims: 1) to develop cross-sectional and longitudinal statistical models of 
AD-associated cognitive dysfunction, 2) to analyze gender differences in AD-associated 
cognitive dysfunction, 3) to examine whether neuropsychiatric symptoms mediated any 
gender effect on AD-associated cognitive dysfunction, and 4) to analyze whether gender 
or neuropsychiatric symptoms increased odds of conversion to AD. Results, limitations, 
and implications of the findings are discussed below for each aim. 
Aim 1: Model cognitive dysfunction in AD 
 The present study generated cross-sectional and longitudinal statistical models of 
the ADNI neuropsychological battery in a mixed sample of older adults who were either 
diagnosed with AD or were non-demented. A cross-sectional, higher-order CFA 
provided good fit to the data, suggesting that the 15 neuropsychological tests of interest 
mapped onto four cognitive domains: memory, language, visuospatial, and 
executive/processing speed. In turn, these four cognitive domains reflected one higher-
order factor of general cognitive dysfunction. This structural model is generally 
consistent with a previous CFA of a slightly different subset of the ADNI 
neuropsychological battery (Park et al., 2012). In Park and colleague’s study, they fit a 
model of five neuropsychological domains (memory, language, visuospatial, attention, 
and executive/processing speed) based on data from ADNI1. In contrast, we analyzed 
neuropsychological data from across all three phases of ADNI (i.e., ADNI1, ADNI-GO, 
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and ADNI2), noting that the neuropsychological battery has changed slightly across 
these phases. For example, Category Fluency-Vegetables and WAIS-R Digit Span and 
Digit Symbol subtests were dropped after ADNI1. Each of these three subtests was part 
of Park and colleague’s CFA, and in fact the two Digit Span subtests (Forward and 
Backward conditions) were the only measures that loaded onto their Attention factor. 
Because our goal was to examine longitudinal cognitive data across all three ADNI 
phases, we adapted this structural model to include key neuropsychological indicators 
from the core ADNI neuropsychological battery. We also added the higher-order factor 
of global cognitive dysfunction, which fit the data well. Our structural model enabled us 
to maximize the cognitive data we analyzed from across all three phases of ADNI, 
thereby analyzing the majority of ADNI participants instead of just those participating in 
ADNI1. Our structural model also enabled us to examine global AD-associated 
cognitive dysfunction, in addition to four discrete cognitive domains.  
The current study also provided an IRT model of how the four cognitive domains 
function across the spectrum of AD-associated cognitive dysfunction. The memory and 
language domains were the most sensitive to mild degrees of cognitive impairment in 
this sample, whereas the executive/processing speed domain was most sensitive to 
moderate degrees of cognitive dysfunction. The visuospatial domain had poorer 
discriminative power than the other three cognitive domains and was only sensitive to 
cognitive impairment at moderate-to-severe levels. These findings generally correspond 
to the pattern of cognitive deterioration in AD and related amnestic conditions (e.g., 
MCI), which is typically marked by early declines in episodic memory and semantic 
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language abilities (e.g., Albert et al., 2011; Caselli et al., 2014; Salmon & Bondi, 2009). 
Visuospatial abilities are impacted as the disease becomes more severe (Salmon & 
Bondi, 2009). Although complex executive functions are known to decline early in the 
course of AD (Albert et al., 2011; Sacuiu et al., 2005; Salmon & Bondi, 2009), the 
executive/processing speed factor in this study functioned best in moderate degrees of 
cognitive dysfunction. This factor was comprised of two processing speed measures but 
only one complex executive measure. Although these measures all assess frontal lobe 
functions, executive abilities and processing speed are not perfectly correlated and in 
fact are often considered as separate (but related) neuropsychological functions. This 
combination of one executive measure and two processing speed measures may explain 
why the executive/processing speed factor was optimally sensitive in moderate degrees 
of AD-associated cognitive dysfunction, rather than in mild degrees.  
We also modeled how each of the 15 neuropsychological tests function across 
the spectrum of AD-associated cognitive dysfunction. Within the memory domain, 
measures of verbal learning and recall (i.e., RAVLT Learning, Short-Delay Recall, 
Delayed Recall; ADAS-Cog Delayed Recall) were more sensitive to mild degrees of 
cognitive dysfunction than measures of recognition memory (i.e., RAVLT Recognition, 
ADAS-Cog Recognition). The RAVLT Learning measure, an index of the number of 
words the participant was able to learn between trial 1 and trial 5, was most sensitive to 
very mild degrees of cognitive dysfunction. This suggests that even older adults who are 
cognitively intact experience mild difficulty with their ability to learn verbal information 
that is presented to them in an auditory manner. Older adults with overt cognitive 
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dysfunction (e.g., those with MCI or AD) have noticeably greater difficulty with this 
task. In fact, at baseline, cognitively intact older adults learned almost six words on 
average (M = 5.87, SD = 2.32), whereas older adults with MCI only learned about four 
words (M = 4.22, SD = 2.57) and older adults with AD only learned two words (M = 
2.16, SD = 1.76) across the five trials. This indicator of verbal learning across a series of 
trials may serve as a sensitive indicator to early cognitive dysfunction.  
The format in which information is presented to participants for learning may 
influence later retrieval and recall. During the RAVLT, a list of words is read aloud to 
the participant for learning, whereas during the ADAS-Cog, the participants hears and 
sees the sequence of words to be learned. The RAVLT appears to be harder, based on 
the fact that the two RAVLT indicators of recall (Short-Delay Recall and Delayed 
Recall) are more optimally sensitive in milder degrees of cognitive dysfunction than the 
ADAS-Cog Delayed Recall subtest. This is likely due to the fact that learning is 
reinforced using two presentations—auditory and visual—on the ADAS-Cog, but just 
using one presentation—auditory—on the RAVLT. Clinical researchers deciding 
between these tests should consider how impaired their sample is; if they are studying 
preclinical, non-demented samples, then the RAVLT may be best at discriminating 
between degrees of cognitive difficulty. On the other hand, if the sample is made up of 
older adults with AD, then the ADAS-Cog may be sufficient for measuring difficulties 
with verbal recall.  
Finally, we found that recognition memory was a less sensitive measure of AD-
associated cognitive dysfunction than learning or free recall. Both the RAVLT and 
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ADAS-Cog recognition subtests functioned equivalently and were most sensitive to 
moderate-to-severe degrees of cognitive impairment, corresponding to participants with 
late MCI to mild AD. For individuals who are cognitively normal or even have 
preclinical AD, recognizing words that were previously presented to them is relatively 
easy (Backman et al., 2005). However, as AD neuropathology spreads throughout the 
brain and cognitive and functional deficits become measurable, memory deficits become 
more obvious. Individuals with AD struggle to encode and consolidate new information 
and thus they cannot recall it, even when presented with a cue such as on a recognition 
memory task (Helkala, Laulumaa, Soininen, & Riekkinen, 1988; Weintraub, Wicklund, 
& Salmon, 2012). 
Among the language measures, Category Fluency-Animals, a measure of 
semantic verbal fluency, was by far the most sensitive measure to mild and moderate 
degrees of AD-associated cognitive dysfunction. The Boston Naming Test was a 
sensitive measure of moderate-to-severe degrees of cognitive dysfunction, but the 
ADAS-Cog Naming subtest was relatively uninformative until cognitive dysfunction 
was fairly severe in this sample. These findings suggest that including a measure of 
verbal fluency (such as Category Fluency-Animals) is likely to be useful as an 
assessment of language in a range of elderly samples, including non-demented and AD 
samples. However, it appears that, in the ADNI sample, only those participants with AD 
experience notable difficulty with confrontation naming on the Boston Naming Test or 
ADAS-Cog Naming subtest. However, even the ADAS-Cog Naming subtest was 
relatively easy for the participants with AD (M = .47, SD = .75) at baseline. It should be 
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noted that these participants had mild AD, so these measures of confrontation naming 
may be more useful among more advanced forms of AD. 
Among the visuospatial measures, both Clock Drawing Test conditions 
functioned best in moderate-to-severe degrees of cognitive impairment, but the ADAS-
Cog Construction subtest was relatively insensitive to capturing any information about 
the range of AD-associated cognitive dysfunction analyzed in this sample. The ADAS-
Cog Construction subtest involves copying mostly basic, two-dimensional geometric 
figures (e.g., circle, diamond), and researchers have found that it is a relatively coarse, 
insensitive measure to mild AD and non-demented cognitive dysfunction (Benge, Balsis, 
Geraci, Massman, & Doody, 2009; Wouters et al., 2012). The result that the Clock 
Drawing Test was optimally sensitive to moderate-to-severe degrees of cognitive 
dysfunction was consistent with other work demonstrating that this measure is not 
suitable to screen for mild forms of cognitive dysfunction such as MCI or very mild AD 
(Ehreke, Luppa, Konig, & Riedel-Heller, 2010; Nishiwaki et al., 2004; Powlishta et al., 
2002). Indeed, in the ADNI sample, both cognitively intact participants and participants 
with MCI performed well on the command (M = 4.68, SD = .63; M = 4.39, SD = .89, 
respectively) and copy (M = 4.88, SD = .37; M = 4.71, SD = .62, respectively) conditions 
at baseline. 
All three executive/processing speed measures were most sensitive in moderate 
degrees of AD-associated cognitive dysfunction. Not surprisingly, Trail Making B, the 
only measure of complex executive functions, was sensitive in milder degrees of 
impairment than Trail Making A or ADAS-Cog Number Cancellation, both of which 
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involve visual processing speed. This is consistent with research showing that executive 
functions decline earlier in the disease process than processing speed (Salmon & Bondi, 
2009; Weintraub, Wicklund, & Salmon, 2012).  
Over the two-year study period of interest, results of repeated-measures 
ANOVAs indicated that an AD sample (i.e., participants who were diagnosed with AD 
within the first two years of their ADNI enrollment) experienced significant linear 
decline in all cognitive domains: memory, language, visuospatial, executive/processing 
speed, and global cognitive functions. We tested for quadratic rates of change, but the 
results were not significant for any domain; rather, a linear slope fit the data best. Other 
studies (e.g., Wilson et al., 2012) have found non-linear rates of global cognitive decline 
due to AD, but these studies have typically examined a much longer study period than 
two years. For example, Wilson and colleagues studied cognitive decline over a period 
of 20 years. It is possible that the linear cognitive decline in the current study was the 
best fit for the shorter time frame of two years, but that AD-related cognitive decline 
may accelerate or decelerate beyond month 24 of ADNI enrollment. As the ADNI 
clinical trials continue, there will be a larger sample size of participants who have 
completed cognitive testing beyond month 24. Additional research should continue to 
analyze patterns of AD-associated cognitive decline in the ADNI database and other AD 
clinical databases. 
Participants who remained non-demented within the two-year period experienced 
relatively little change in their memory, language, visuospatial, executive/processing 
speed, or global cognitive functions. This seems inconsistent with the body of literature 
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showing steady linear declines in numerous cognitive abilities (e.g., processing speed, 
language skills, visuospatial functions) in non-diseased aging (e.g., Bopp & Verhaeghen, 
2005; Caselli et al., 2014; Salthouse, 2004, 2009a). The lack of cognitive decline in our 
non-demented sample may be related to the somewhat short two-year time period that 
was analyzed; possibly a longer timeframe could have better captured these age-related 
declines. Alternatively, perhaps this sample of non-demented older adults remained 
stable for these specific neuropsychological measures, but might have shown decline on 
different cognitive measures. For example, there may have been a ceiling effect on the 
ADAS-Cog, such that some of the subtests (e.g., copying basic geometric figures, 
naming common household items) were easy enough for these non-demented adults to 
complete successfully; therefore these ADAS-Cog subtests may be unable to capture 
subtle cognitive difficulties. A neuropsychological battery that is composed of more 
complex, difficult assessments may yield a different pattern of change for this non-
demented sample.  
The discrepancy between the age-related declines reported in the literature and 
the cognitive stability in this sample of non-demented older adults may also be related to 
unique characteristics of this sample. It may be that non-demented older adults who 
voluntarily participate in a clinical trial like ADNI are cognitively healthier than their 
peers. This could be related to the fact that participants were excluded from ADNI 
enrollment if they had a history of certain neurological or medical conditions (e.g., 
seizure disorder, infarctions or lesions on brain scans, history of head trauma, alcohol 
abuse within the previous two years) or were currently using certain medications (e.g., 
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sedative hypnotics, neuroleptics, certain antidepressants). Exclusion criteria such as 
these yielded an elderly sample that was much more physically healthy than the general 
older adult population in America, which may have also translated into greater cognitive 
health and stability over the two-year period.  
In addition, non-demented adults are likely to show a practice effect on the 
cognitive measures, especially considering that many of them completed 
neuropsychological testing just six to twelve months apart (i.e., at baseline, month 6, 
month 12, month 24). Supporting this interpretation, the ADNI sample was not 
demographically representative of the general United States population; the sample was 
highly educated, with nearly a college education on average. Highly educated older 
adults have been shown to demonstrate an even larger practice effect than less educated 
older adults (Karlamangla et al., 2009). It is likely, then, that the high education level of 
the ADNI sample contributed to the cognitive stability seen in non-demented 
participants. 
The high mean education level may also be indicative of a sample that comes 
from a higher socioeconomic status (SES) background, as is true of many clinical trial 
samples (Gul & Ali, 2010), although other indicators of SES (e.g., income) were not 
measured in the ADNI sample. Individuals from a higher SES background tend to have 
greater access to certain protective factors for cognitive health, such as better medical 
care and lifelong educational experiences, such that they can build up a larger cognitive 
reserve relative to individuals from a lower SES background. In fact, Karlamangla and 
colleagues (2009) found that high SES older adults performed better than low SES older 
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adults cross-sectionally, but SES was not associated with rate of cognitive decline. SES 
may be partially related to the cognitive stability of the non-demented ADNI sample, but 
it is likely that other factors such as practice effects and the selection of the ADNI 
neuropsychological battery were more greatly involved.  
Aim 2: Analyze gender differences in AD-associated cognitive dysfunction 
 The present study analyzed gender differences at baseline, as well as whether 
there were significant gender differences in trajectories of cognitive change for both the 
AD group and the non-demented group. At baseline, the results for the overall sample 
revealed significant gender differences in latent global and memory scores and a 
marginally significant gender difference in latent visuospatial scores. Men had worse 
cognitive performance in each of these areas than women. However, it appears that this 
pattern was driven primarily by gender differences in the non-demented group. Non-
demented men had significantly poorer latent global and memory scores than non-
demented women at baseline, month 12, and month 24. This women’s advantage in the 
memory domain, comprised of verbal episodic memory measures, is consistent with 
previous studies (Barnes et al., 2003; Munro et al., 2012). Unlike the results of these 
previous studies, though, non-demented women did not perform worse than non-
demented men for visuospatial or language abilities.  
 Diagnostic status moderated the effect of gender such that there was the reverse 
pattern of gender differences among participants with AD. In this group, women 
performed worse than men in latent global, memory, language, and executive domains; 
however, this gender difference was not statistically significant at baseline. At month 12 
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and month 24, the poorer memory performance by women with AD relative to men with 
AD was statistically significant. This deficit in verbal memory for women mirrors other 
recent findings in AD samples (e.g., Chapman et al., 2011; Pusswald et al., 2015). In 
addition, there was a marginally significant trend for women to have worse latent global 
cognitive scores than men at month 12. A recent meta-analysis by Irvine and colleagues 
(2012) found that women showed small but consistent deficits in all areas of cognitive 
functioning relative to men in AD samples, but in the present study, gender differences 
in AD-associated cognitive dysfunction were restricted to memory and global cognitive 
functions. 
 In addition to considering mean differences in cognitive performance, we 
analyzed whether there were gender differences in the statistical models of AD-
associated cognitive dysfunction. At baseline, we were interested in whether the 
cognitive domains and individual items (subtests) functioned differently for men versus 
women. Using IRT DIF analyses, we found that all of the cognitive subtests functioned 
relatively equivalently for men and women with the exception of the Clock Drawing 
Test-command condition. This subtest was more strongly related to the latent continuum 
of AD-associated cognitive dysfunction and discriminated in relatively milder degrees of 
cognitive dysfunction for men than women. For both men and women, this subtest 
provided the most amount of information about moderate-to-severe degrees of AD-
associated cognitive dysfunction. This segment of the latent continuum in the current 
sample corresponds to MCI and mild AD. These results suggest that Clock Drawing 
Test-command condition is a more sensitive assessment of visuospatial abilities in men, 
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and that it can capture somewhat milder cognitive problems in men than women. 
According to our IRT model, in moderate-to-severe degrees of latent cognitive 
dysfunction, men and women with the same degree of latent AD-associated cognitive 
dysfunction performed differently on the Clock Drawing Test-command condition (as 
represented by the gap between the two item curves in Figure 12). It may be that in the 
mildest stages of AD, men develop subtle visuospatial difficulties slightly earlier than 
women. Alternatively, perhaps the Clock Drawing Test is a more precise, sensitive 
assessment of AD-associated visuospatial dysfunction in men than women.  
 Longitudinally over the two-year period, women with AD had a different rate of 
decline in their memory compared to men with AD. Both men and women with AD 
demonstrated quadratic rates of memory decline, but the parabolas representing each 
gender’s memory decline over the two-year period was a different shape. Women with 
AD had an “upside down” U-shaped parabola, indicating that they had fast decline in 
their memory between baseline and month 12; the rate of their memory decline 
decelerated from month 12 to month 24. In contrast, men with AD had slightly slower 
memory decline from baseline to month 12, but the rate of memory decline accelerated 
from month 12 to month 24, as depicted by the U-shaped parabola. It is uncertain 
whether there would be gender differences in rate of memory decline after month 24 of 
ADNI enrollment. It is possible that men and women had slightly different rates of 
memory decline within this two-year period, but that both sexes experienced equivalent 
rates of decline during subsequent years that were not examined for these analyses. 
Alternatively, it is possible that this gender difference in rate of memory decline 
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persisted after month 24. Further research should examine gender differences in AD-
associated memory dysfunction within a longer study period to clarify this uncertainty. 
Given the general dearth of research on sex differences in specific domains of 
cognitive change in AD, it is impossible to know whether this gender difference in the 
trajectory of memory decline is specific to the ADNI sample or reflective of a true 
gender difference in AD. The current results did not indicate any gender differences in 
rate of change for latent global, language, visuospatial, or executive/processing speed in 
the AD group. Two other studies have examined gender differences in global cognitive 
decline and yielded mixed results. Holland and colleagues (2013) found faster global 
decline in women than men with MCI, but equivalent global decline in men and women 
with AD. On the other hand, Tschanz and colleagues (2011) showed that females with 
AD had faster global decline than men with AD. These studies analyzed change on the 
CDR-SB, ADAS-Cog, and MMSE, which are all widely used measurements used to 
stage dementia severity. In contrast, the present study derived its global cognitive 
dysfunction score from a battery of neuropsychological tests. Additional research is 
needed to further tease apart the potential gender difference in global AD-associated 
cognitive dysfunction, as well as specific domains of cognitive functioning. It is critical 
to better understand whether men and women experience a slightly different cognitive 
profile and/or cognitive trajectories of AD, as the current results suggest regarding 
differing rates of memory decline. 
 Although there was not a gender difference in the rate of global cognitive 
decline, there was an interaction between gender and diagnostic status for global 
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cognitive dysfunction averaged across the three time points. This finding revealed that 
women had worse global cognitive dysfunction than men across these time points in the 
AD group, but the opposite was true in the non-demented group: non-demented men had 
worse global cognitive dysfunction than non-demented women averaged across the two-
year period. Among the non-demented sample, there were no gender differences in rate 
of cognitive change over the three time points; both non-demented men and women 
experienced relatively flat rates of cognitive change, reflecting stable cognitive 
performance.  
Aim 3: Examine whether neuropsychiatric symptoms mediate potential effects of 
gender on AD-associated cognitive dysfunction 
 Neuropsychiatric symptoms were much more common in the AD sample than the 
non-demented sample, consistent with other research (e.g., Canevelli et al., 2013; Geda 
et al., 2008; Peters et al., 2015). Despite this, the results of mediation analyses did not 
support the hypothesis that neuropsychiatric symptoms would mediate a gender 
difference in cognitive dysfunction among those with AD. As described above, the 
primary gender difference in the AD sample was in memory: women had poorer 
memory performance at month 12 and month 24. After controlling for age and 
education, gender remained a significant predictor of memory performance at month 12 
and was a marginally significant predictor of memory dysfunction at month 24. 
However, neuropsychiatric symptoms did not mediate these effects. At baseline, gender 
did not significantly predict memory dysfunction or any of the other cognitive domains 
for the AD group. Cross-sectional mediation by neuropsychiatric symptoms therefore 
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could not be demonstrated in this AD group. Longitudinally, men and women had 
differing patterns of memory decline over the two-year period, but this gender difference 
remained statistically significant even after controlling for neuropsychiatric symptoms. 
Neuropsychiatric symptoms did not account for gender differences in rates of AD-
associated memory decline.  
For the entire sample at baseline, neuropsychiatric symptoms did mediate the 
effect of gender on executive/processing speed dysfunction. When diagnostic status was 
entered as a moderating variable, results indicated that this mediation held up only for 
the non-demented sample. This indicates that any gender difference in 
executive/processing speed difficulties in this non-demented sample is likely driven by 
neuropsychiatric distress. In the present non-demented sample, men performed worse 
than women on executive/processing speed measures, but they also had higher 
neuropsychiatric severity scores. This mediation finding suggests that controlling for 
neuropsychiatric symptoms adjusted the men’s executive/processing speed scores to be 
closer to the women’s scores among the non-demented sample.  
Brodaty and colleagues (2012) found that neuropsychiatric symptoms were 
related to worse executive functioning among non-demented older adults. Depression, 
anxiety, and apathy have also been linked to poorer performance on executive functions 
and processing speed (Brodaty et al., 2012; Drijgers et al., 2011). Between 13-18% of 
men had partner-endorsed symptoms of depression, anxiety, and apathy at baseline in 
the current study, which may have contributed to their executive/processing speed 
difficulties. Men experienced depression and anxiety at relatively similar rates as 
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women, though, and there was only a slight gender difference in rates of apathy. 
Approximately 13% of men had apathy at baseline, relative to 9% of women. Therefore, 
it seems unlikely that these specific symptoms had a unique impact on executive 
functioning. Rather, it may be that overall neuropsychiatric symptom severity accounted 
for a portion of executive dysfunction, particularly in men.  
Longitudinally, the overall effect of gender on average memory dysfunction 
across the three time points was no longer significant after controlling for 
neuropsychiatric symptoms. This result was not moderated by diagnostic status. Because 
the majority of the overall sample was non-demented, this effect was likely heavily 
influenced by the pattern of gender differences among the non-demented individuals for 
memory. Non-demented men had significantly worse memory at each of the three time 
points than non-demented women, and they also had significantly higher 
neuropsychiatric scores. Again, it appears that partialing out the influence of 
neuropsychiatric distress reduced the gap between men and women’s performance on 
memory, but primarily among older adults who were non-demented. No known previous 
studies have examined the interplay between neuropsychiatric symptoms and gender on 
AD-associated cognitive decline, so these findings are a preliminary contribution to the 
literature. More research needs to be done to further analyze these questions. 
Although neuropsychiatric symptoms generally did not appear to mediate a 
gender difference in cognitive dysfunction, there was preliminary evidence of an 
independent contribution of neuropsychiatric symptoms to the progression of AD-
associated cognitive dysfunction. Neuropsychiatric symptoms significantly interacted 
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with time for language dysfunction across the entire sample of 1045 participants, 
suggesting that language decline depended on neuropsychiatric status. A handful of 
previous studies have also found that certain neuropsychiatric symptoms, such as apathy, 
anxiety, agitation, euphoria, or sleep problems, have been linked with faster cognitive 
decline in clinical samples (Brodaty et al., 2012; Canevelli et al., 2013; Pocnet et al., 
2015). The results of this study suggest that overall severity of neuropsychiatric 
symptoms may influence the rate of decline in language. This is a preliminary finding, 
so additional research should seek to characterize the effects of neuropsychiatric 
symptoms on AD-associated cognitive trajectories. 
Men had more problems with neuropsychiatric symptoms than women in both 
the AD and non-demented samples. This is inconsistent with the general elderly 
population, where women tend to have more neuropsychiatric symptoms. Even at the 
symptom level, findings were inconsistent. Women did not have higher rates of 
depression or anxiety, as numerous studies have found in late life (Apostolova & 
Cummings, 2008; Brodaty et al., 2015; Van der Mussele et al., 2014) and throughout the 
lifespan (Leach et al., 2008; McLean & Anderson, 2009; Seeman, 1997). It is possible 
that the higher rates of neuropsychiatric symptoms in men than women in this sample is 
related to the particular neuropsychiatric assessments analyzed for this study. Both the 
NPI and NPI-Q depend on caregiver report rather than self-report by the study 
participant. It is possible that relying on an informant may affect the pattern of gender 
differences in neuropsychiatric symptoms, particularly if the informant is also the 
patient’s caregiver. The only other known study examining gender differences on 
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caregiver-report instruments (specifically the NPI or NPI-Q) was conducted by Brodaty 
and colleagues (2015), using an Australian sample of older adults with AD and other 
types of dementia. This study found higher rates of overall neuropsychiatric symptoms 
for men, similar to the present results. Brodaty also showed that men were more likely to 
demonstrate apathy, agitation, disinhibition, irritability, and delusions. The present study 
did find slightly higher rates of each of these symptoms among men relative to women 
except delusions. However, the current study did not find higher rates of depression, as 
Brodaty’s team did. The handful of other studies that have considered gender differences 
in neuropsychiatric symptoms among older adults (e.g., Apostolova & Cummings, 2008; 
Van der Mussele et al., 2014) utilized a mixture of self-report and other-report measures. 
Caregivers are likely to be more distressed about the patient’s neuropsychiatric 
symptoms than clinicians or perhaps even the patients themselves if the patients are 
demonstrating limited insight into their symptoms. In fact, there may even be gender 
differences in the amount of distress experienced by caregivers, with some studies 
finding that female caregivers reported higher levels of personal distress and depressive 
symptoms, as well as more patient behavioral problems (Pinquart & Sorensen, 2006; 
Schulz & Williamson, 1991). Data are not available on the gender of each ADNI 
participant’s caregiver/informant, but it is likely that female caregivers accompanied 
most of the male participants, particularly for the 88% of male subjects who were 
married. Therefore, there may be an interaction between the sex of the caregiver and the 
sex of the patient that influences severity of reported neuropsychiatric symptoms. This 
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could explain why men in the current sample had higher levels of neuropsychiatric 
symptoms. 
Aim 4: Analyze rates of conversion to AD by gender and neuropsychiatric 
symptoms.  
Results of a binary logistic regression model revealed that men and women did 
not have different odds of converting to AD. The women in this ADNI sample had an 
incidence rate of conversion to AD that was slightly less than the incidence rate for men: 
approximately 13% of women and 16% of men converted to AD between baseline and 
month 24. Many studies have found that men and women have similar incidence rates of 
AD (e.g., Bachman et al., 1993; Ganguli et al., 2000; Hebert et al., 2001), whereas other 
studies have shown significantly higher incidence rates in women (e.g., Aronson et al., 
1990; Fratiglioni et al., 1997, 2000; Gao et al., 1998). These latter studies primarily were 
conducted with European, Asian, or regional American samples. In the Cache County 
Study, a population-based study in Utah, Zandi and colleagues (2002) found similar 
incidence rates for American men and women between ages 65 to 80; it was only after 
the age of 80 that women had higher incidence rates of AD than men. The majority of 
the ADNI sample (79% of participants) was between 55 to 79 years old, so this may 
indicate why incidence rates were similar for men and women. Perhaps if the ADNI 
sample had more participants in their 80s and 90s, a gender difference may have 
emerged in incidence rates of AD.  
Furthermore, the ADNI sample is not representative of the United States 
demographics, as evidenced by the high mean level of education and racial/ethnic 
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homogeneity (94% identified as white/Caucasian and 97% identified as non-
Hispanic/non-Latino). Although studies in the United States have shown mixed results 
regarding a gender difference in incidence rates of AD, many have utilized samples that 
were representative of their regional population (e.g., Bronx, Cache County in Utah) and 
had greater ethnic diversity. Because the ADNI sample is a homogeneous clinical 
sample, it is difficult to determine whether there are gender differences in incidence rates 
of AD among the larger, more diverse population of Americans with AD. Population-
based studies should continue to examine whether women are more vulnerable to 
developing AD than men. In the ADNI sample, there was no significant gender 
difference in incidence rates.  
 The binary logistic regression model revealed that baseline neuropsychiatric 
symptoms did increase odds to converting to AD by 1.20 for every one-unit increase in 
the total NPI severity composite score. Rosenberg and colleagues (2013) also found that 
neuropsychiatric symptoms increased the risk of developing AD dementia. Other studies 
have shown a unique predictive role of specific neuropsychiatric symptoms, including 
depression, anxiety, agitation, and apathy (e.g., Banks et al., 2014; Brodaty et al., 2012; 
Copeland et al., 2003; Palmer et al., 2011; Van der Mussele et al., 2014). In the present 
study, participants who converted to AD between baseline and month 24 had 
significantly higher NPI severity composite scores at each time point. Participants who 
converted from MCI to AD were more likely (67-82%) to endorse any neuropsychiatric 
symptom than participants who did not convert from MCI to AD (56-62%). Individuals 
who converted from MCI to AD were also more likely to endorse most of the individual 
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neuropsychiatric symptoms than individuals who did not convert from MCI to AD 
during the study period. These results underscore the notion that neuropsychiatric 
symptoms may influence the progression and cognitive expression of AD-associated 
cognitive dysfunction independent of gender.  
Limitations and Conclusions  
 In sum, this study achieved four main aims: 1) to model AD-associated cognitive 
dysfunction cross-sectionally and longitudinally, 2) to analyze gender differences in AD-
associated cognitive dysfunction, 3) to examine whether neuropsychiatric symptoms 
mediate any gender effect on AD-associated cognitive dysfunction, and 4) to analyze 
whether gender or neuropsychiatric symptoms increased odds of conversion to AD. This 
study provided cross-sectional and longitudinal models of AD-associated cognitive 
dysfunction in IRT and SEM frameworks. In the ADNI sample, memory and language 
measures were the most sensitive to mild degrees of AD-associated cognitive 
impairment. In particular, the RAVLT measures of learning and free recall and the 
Category Fluency-Animals test provided the most information about cognitive 
dysfunction. Other cognitive measures functioned best at more moderate degrees of AD-
associated cognitive dysfunction, corresponding to MCI and mild AD. The results also 
confirmed the expected pattern of individuals with AD performing worse than non-
demented participants cross-sectionally. The participants with AD demonstrated linear 
rates of decline in all cognitive domains, whereas the non-demented participants showed 
flat, stable rates of change in their cognitive functions. 
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 There were select gender differences in AD-associated cognitive dysfunction. 
Among those with AD, women had significantly worse memory dysfunction than men. 
Women with AD had marginally worse global cognitive dysfunction than men with AD 
at month 12. Women and men with AD had different rates of memory decline as well. 
The reverse pattern was true in the non-demented sample: men had worse global 
cognitive and memory performance than women. This moderation of gender differences 
in cognitive dysfunction by diagnostic status is interesting and raises additional 
questions. Does the AD neuropathological process somehow affect women differently, 
so that they have stronger memory performance when they are non-demented but then 
experience a sharper decline in memory than men also affected by AD? If AD does have 
a different neurobiological impact on women, then what causal factors are involved? 
 The hypothesis that neuropsychiatric symptoms would mediate a gender effect 
on cognitive dysfunction was generally not supported. Women had significantly worse 
memory dysfunction and a different rate of memory decline than men in the AD group, 
but this gender effect was not attenuated after controlling for neuropsychiatric 
symptoms. We need additional research to uncover what mechanisms might account for 
this important gender difference in AD-associated cognitive dysfunction.  
Neuropsychiatric symptoms did mediate the effect of gender on 
executive/processing speed dysfunction, but only in the non-demented sample; non-
demented men had worse executive/processing speed performance and higher levels of 
neuropsychiatric symptom severity. Controlling for neuropsychiatric symptoms reduced 
the gender difference for performance on executive/processing speed measures. It may 
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be that neuropsychiatric symptoms are more closely related to executive/processing 
speed problems in non-demented men than in non-demented women. 
There are some limitations of the current study that should be noted. First, the 
ADNI neuropsychological battery has key weaknesses. This battery has several 
measures of verbal memory, but there are no measures of visual memory. In terms of 
language, there are only measures of semantic language and speech production, 
involving components of confrontation naming (Boston Naming Test) and verbal 
fluency (Category Fluency-Animals). Only ADNI1 contained any assessments of 
attention, but it was restricted to the WAIS-R Digit Span test. Neither the ADNI-GO nor 
ADNI2 neuropsychological batteries include measures of pure attention, although of 
course attentional abilities are implicit in other measures such as Trails A (visual 
processing). There are relatively few measures of executive abilities, especially complex 
executive functions that are known to decline early in AD. The only executive measure 
in the core ADNI neuropsychological battery was Trails B, which involves working 
memory, visual set shifting, and graphomotor speed. Finally, assessment of visuospatial 
abilities is restricted primarily to the Clock Drawing Test, which also is sensitive to 
executive functions (Royall, Mulroy, Chiodo, & Polk, 1999). The neuropsychological 
battery would have been strengthened by the inclusion of more complex measures that 
are sensitive to milder degrees of cognitive dysfunction, as well as additional measures 
to better assess a broader range of cognitive abilities, including basic attention, visual 
memory, executive functions, and visuospatial abilities.  
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Certain limitations of the ADNI sample relevant to gender should also be noted. 
Men are overrepresented in the ADNI sample, both among those with AD and those who 
were non-demented. Almost two-thirds of individuals in the United States with AD are 
women (Alzheimer’s Association, 2015; Carter et al., 2012), but in this sample only 41% 
of the participants with a diagnosis of AD at month 24 were women. The Aging, 
Demographics, and Memory Study (Plassman et al., 2007) found that among Americans 
over the age of 71 years, 11.48% of women and 7.05% of men had AD; in this ADNI 
sample, 22.4% of women and 24.9% of men had AD by month 24. The rates of AD were 
higher in this sample because of ADNI’s priority to recruit a clinical sample of 
participants with AD and MCI. Even so, more men had AD than women in the ADNI 
sample, which is contrary to the pattern in the general population. Even among the non-
demented sample, only 44% were female. This sample characteristic is discrepant from 
the general population in the United States over the age of 65 years, of which 
approximately 56% are women (Administration on Aging et al., 2015). 
There were also differences in marital status that may be pertinent to the results. 
In the general United States population of adults 65 years and older, 70% of men and 
only 45% of women are married; 12% of men and 34% of women are widowed 
(Administration on Aging et al., 2015). In the ADNI sample, approximately 88% of the 
male participants were married and 62% of the female participants were married. 
Women were much more likely to be widowed (19%) or divorced (14%) compared to 
the men in the sample (5% widowed and 5% divorced). The likelihood of being married 
was much greater in the ADNI sample than in the general United States population, but 
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the gender difference in marital status remained, with men being more likely to be 
married than women. Among the AD sample, 66% of women and 93% of men were 
married. Some studies have found that widowed and never-married older adults have 
faster rates of cognitive decline than married older adults (Karlamangla et al., 2009). 
This risk of faster cognitive decline may be due to social factors, since married older 
adults have a built-in social support in their spouse, whereas widowed and never-married 
older adults may have fewer social opportunities. Because a greater proportion of 
women in the ADNI sample were married than in the general population (62% vs. 45%, 
respectively), this might partially explain the fact that women in ADNI had lower levels 
of depression and anxiety than would be expected. The gender differences in marital 
status may also contribute to the varying rates of memory decline in women compared to 
men with AD, but it likely had a small effect since there were not any other significant 
gender differences in AD-associated cognitive trajectories.  
Unfortunately, the ADNI database does not include information about 
cardiovascular disease, estrogen changes (e.g., age at menopause, use of hormone 
replacement therapy), or many other variables that may contribute to the gender gap in 
AD. In the current ADNI sample, men (M = 16.63, SD = 2.64) were significantly more 
educated than women (M = 15.44, SD = 2.78), although the mean difference was only 
one year. Despite this possible indicator of slightly higher cognitive reserve in the male 
participants, men actually performed more poorly than women in the non-demented 
sample. Instead, other factors (e.g., recruitment strategies) may have contributed to the 
pattern of gender differences in the ADNI sample. These non-representative 
  144 
characteristics of men and women in ADNI unfortunately limit the generalizability of 
the present results to other populations.  
Participants in ADNI had relatively mild degrees of neuropsychiatric problems, 
which also limits the generalizability of these results. Participants were excluded from 
ADNI if they had a history of major depression within the year prior to enrollment or if 
they exhibited notable agitation or behavioral problems that might interfere with their 
research study compliance. This may have created a restricted sample that is not 
representative of the general older adult population or the AD population. Some of the 
previous studies that have examined gender differences in neuropsychiatric symptoms 
have utilized nursing home samples (e.g., Buchanan et al., 2004; Zuidema et al., 2009), 
which are likely to be more cognitively and neuropsychiatrically impaired than the 
ADNI sample, which includes community-dwelling older adults. Thus, based on the 
characteristics of the ADNI sample, the results may not fully capture the role that 
neuropsychiatric symptoms play in AD-associated cognitive dysfunction. 
 Despite these limitations, the current study provided some key findings that have 
important implications. First, among the AD sample, women had worse memory 
performance than men and exhibited different rates of memory decline. Additional 
research should further explore this topic and seek to discover why this gender 
difference may exist. We need research that examines whether the AD neuropathological 
process differentially impacts women relative to men at a basic neurobiological level or 
whether other factors may be involved. Neuropsychiatric symptoms did not mediate this 
gender effect, but other sociocultural, psychological, or environmental factors may be 
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involved. There is likely a complex web of factors, including variables such as estrogen, 
cardiovascular disease, life expectancy, sociocultural roles and support, and 
psychological health that contribute to women’s increased risk of developing AD. 
Although the current study was unable to determine the cause of the gender difference in 
AD, results add to the literature by clearly demonstrating the presence of a gender 
difference in memory and they rule out a contribution of neuropsychiatric symptoms in 
the ADNI sample. It is important to remember that these findings are not generalizable 
to the general older adult population, though, given the key limitations of the ADNI 
sample as described above. It is possible that neuropsychiatric symptoms might mediate 
gender differences in cognitive dysfunction in other AD samples. 
 Although neuropsychiatric symptoms did not mediate this gender effect on 
memory in the AD group, there was evidence that overall neuropsychiatric symptom 
severity increased odds of converting to AD. Results also showed that neuropsychiatric 
symptom severity interacted with time for decline in language functions. These initial 
findings are consistent with prior studies and suggest that neuropsychiatric symptoms 
may be a risk factor not only for converting to AD but also for faster cognitive decline. It 
is critical for clinicians to assess neuropsychiatric symptoms in older adults as a potential 
proxy for risk of converting to AD. Furthermore, clinicians should emphasize early 
treatment of these psychological symptoms to potentially decrease the rate of cognitive 
decline due to AD and improve psychological health. Finally, additional research should 
examine the role of neuropsychiatric symptoms in a more representative population of 
older adults, especially older adults with AD. Considering that women are more likely to 
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suffer from depression and anxiety throughout their lifetime and in late life, it may still 
be true that these negative affect symptoms influence cognitive dysfunction, despite the 
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